 
 
Official Title:  P20 Extending Sleep to Reverse Metabolic Syndrome in Middle -Aged 
Adults: Acceptability and Feasibility of a Sleep Intervention   
NCT Number : [STUDY_ID_REMOVED]  
Study Number:  18-[ZIP_CODE]  
Document Type:  Study  Protocol and Statistical Analysis Plan 
Date of the 
Document:  • 9/29/2022  
 
 
 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  Page i  
 
P20 Extending Sleep to Reverse the Metabolic Syndrome in Middle- 
Aged Adults: Acceptability and Feasibility of a Sleep Intervention  
A single site pi[INVESTIGATOR_616316] a twelve- week sleep extension 
intervention, self -management for adequate sleep intervention (SASI), in community -dwelling, middle - aged 
adults with the metabolic syndrome.  
Principal Investigator:  [INVESTIGATOR_616317] [ADDRESS_817075], [LOCATION_001], NY [ZIP_CODE]  
[EMAIL_11723] 732 -693-8081 
Additional  
Investigators:  Azizi Seixas  
NYU School of Medicine, Department of Population Health  
[ADDRESS_817076], [LOCATION_001], NY [ZIP_CODE] 
[EMAIL_11724] 646- 501-[ADDRESS_817077], [LOCATION_001], NY [ZIP_CODE] 
[EMAIL_11725] [ADDRESS_817078], [LOCATION_001], NY [ZIP_CODE] [EMAIL_6033] 212- 992-[ADDRESS_817079], [LOCATION_001], NY [ZIP_CODE]  
Girardin.Jean -[EMAIL_11726]  
[PHONE_12746] 
Gary Yu, PhD  
NYU Rory Meyers College of Nursing [ADDRESS_817080], [LOCATION_001], NY [ZIP_CODE] 
[EMAIL_11727] 
[PHONE_12747] 
 
Bradley Aouizerat, PhD  
Bluestone Center for Clinical Research  
[ADDRESS_817081], Room 1024S, [LOCATION_001], NY [ZIP_CODE]  
[EMAIL_11728] 
[PHONE_6406]  
NYULMC Study Number:  18-[ZIP_CODE]  
Funding Sponsor:  National Institutes of Health  
National Institute of Nursing Research  
1P20NR018075 -01 
ClinicalTrials.gov  Include the National Clinical Trial (NCT) Number assigned once the 
trial is registered on the ClinicalTrials.gov.  [STUDY_ID_REMOVED]  

Study Number: 18-[ZIP_CODE] Page ii 
Version Date: February  19, 20 21 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  Initial version: June 1, 2018  
Amended:  
Amended:  
Statement of Compliance  
This study will be conducted in accordance with the Code  of Federal Regulations on the Protection of 
Human Subjects (45 CFR Part 46), any other applicable US government research regulations, and 
institutional research policies and procedures. The Principal Investigator [INVESTIGATOR_7433], or changes to the protocol will take place without prior agreement from the sponsor and documented 
approval from the Institutional Review Board (IRB), except where necessary to eliminate an immediate 
hazard(s) to the trial participants. All personnel involved in  the conduct of this study have completed Human 
Subjects Protection Training.
  
Study Number: 18-[ZIP_CODE] Page iii 
Version Date: February  19, 20 21 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  Table of Contents  
EXTENDING SLEEP TO REVERSE METABOLIC SYNDROME IN MIDDLE -AGED ADULTS:  
ACCEPTABILITY AND FEASIBILITY OF A SLEEP INTERVENTION.........................................................I  
PROTOCOL SUMMARY..............................................................................................................................1  
SCHEMATIC OF STUDY DESIGN...............................................................................................................3  
KEY ROLES.................................................................................................................... .............................4  
1 INTRODUCTION, BACKGROUND INFORMATION AND SCIENTIF IC RATIONALE........................7  
1.1 B ACKGROUND INFORMATION AND RELEVANT LITERATURE ................................................................7 
1.2 R ATIONALE ....................................................................................................................................8 1.3 
POTENTIAL RISKS & BENEFITS ........................................................................................................9  
 1.3.1  Known Potential Risks.............................................................................................................9  
 1.3.2  Known Potential Benefits ......................................................................................................10  
2 OBJECTIVES AND PURPOSE.........................................................................................................10  
2.1 P RIMARY OBJECTIVE ....................................................................................................................11 
2.2 S ECONDARY OBJECTIVES (IF APPLICABLE ).....................................................................................11  
3 STUDY DESIGN AND ENDPOINTS..................................................................................................11  
3.1 D ESCRIPTION OF STUDY DESIGN ..................................................................................................11 
3.2 S TUDY ENDPOINTS ......................................................................................................................11  
 3.2.1  Primary Study Endpoints.......................................................................................................11  
 3.2.2  Secondary Study Endpoints......................................................... .........................................11  
 3.2.3  Exploratory Endpoints...........................................................................................................12  
4 STUDY ENROLLMENT AND WITHDRAWAL ..................................................................................12  
4.1 INCLUSION CRITERIA ....................................................................................................................12 
4.2 E XCLUSION CRITERIA ...................................................................................................................12 
4.3 V ULNERABLE SUBJECTS ...............................................................................................................13 
4.4 S TRATEGIES FOR RECRUITMENT AND RETENTION ..........................................................................13  
 4.4.1  Electronically -posted flyers ...................................................................................................13  
 4.4.2  Advertising in the community................................................................................................13  
 4.4.3  Posted/distributed flyers........................................................................................................[ADDRESS_817082] study participants..........................................................................................................14  
 4.4.6  Use of DataCore/Epic Information for Recruitment Purposes...............................................14  
 4.4.7  Research Match............................................................................................................... .....14  
 4.5 D URATION OF STUDY PARTICIPATION ............................................................................................15  
 4.5.1  Reasons for Withdrawal or Termination................................................................................15  
 4.5.2 Handling of Participant Withdrawals or Termination..............................................................15  
 4.5.3  Premature Termination or Suspension of Study....................................................................15  
5 BEHAVIORAL/SO CIAL INTERVENTION.........................................................................................15  
 5.1 S TUDY BEHAVIORAL OR SOCIAL INTERVENTION (S) DESCRIPTION ....................................................[ADDRESS_817083] Compliance wi th Study Intervention.................................................16  
6 STUDY PROCEDURES AND SCHEDULE .......................................................................................16  
Study Number: 18-[ZIP_CODE] Page iv 
Version Date: February  19, 20 21 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017   6.1 S TUDY PROCEDURES /EVALUATIONS .............................................................................................[ADDRESS_817084] of Care Study Procedures ........... ..........................................................................19  
 6.2 L ABORATORY PROCEDURES /EVALUATIONS ...................................................................................19  
 6.2.1  Clinical Laboratory Evaluations.............................................................................................19  
 6.2.2  Other Assays or Procedures .................................................................................................1 9 
 6.2.3  Specimen Preparation, Handling, and Storage.....................................................................19  
 6.2.4  Specimen Shipment............................................................................................................ ..20 
 6.3 S TUDY SCHEDULE .......................................................................................................................20  
 6.3.1  Screening..............................................................................................................................19  
 6.3.2  Enrollment/Baseline ..............................................................................................................19  
 6.3.3  Intermediate Visits.................................................................................................................20  
 6.3.4  Final Study Visit (within 3 weeks of completing SASI)....................................................22  
 6.3.5  Withdrawal Visit.....................................................................................................................22  
 6.3.6  Unscheduled Visit ........................................................................................................... ......22  
 6.4 C ONCOMITANT MEDICATIONS , TREATMENTS , AND PROCEDURES ....................................................23  
7 ASSESSMENT OF SAFETY ........................................................................................................ .....23  
 7.1 S PECIFICATION OF SAFETY PARAMETERS ......................................................................................23  
 7.1.1  Definition of Adverse Events (AE).........................................................................................23  
 7.1.2  Definition of Serious Adverse Events (SAE).........................................................................23  
 7.1.3  Definition of Unanticipated Problems (UP)............................................................................23  
 7.2 C LASSIFICATION OF AN ADVERSE EVENT .......................................................................................24  
 7.2.1  Severity of Event...................................................................................................................24  
 7.2.2  Relationship to S tudy Intervention ........................................................................................24  
 7.2.3  Expectedness........................................................................................................................24  
 7.3 T IME PERIOD AND FREQUENCY FOR EVENT ASSESSMENT AND FOLLOW -UP ....................................24  
 7.4 R EPORTING PROCEDURES – NOTIFYING THE IRB..........................................................................25  
 7.4.1  Adverse Event Reporting.... ..................................................................................................25  
7.4.2 Serious Adverse Event Reporting.........................................................................................25 
7.4.3 Unanticipated Problem Reporting.........................................................................................25  
 7.4.4  Reporting of Pregnancy ........................................................................................................26  
7.5 R EPORTING PROCEDURES – N OTIFYING THE STUDY SPONSOR ......................................................26 
7.6 R EPORTING PROCEDURES – P ARTICIPATING INVESTIGATORS .........................................................27 
7.7 S TUDY HALTING RULES................................................................................................................27 
7.8 S AFETY OVERSIGHT .....................................................................................................................27  
8 CLINICAL MONITORING..................................................................................................................2 9 
9 STATISTICAL CONSIDERATIONS..................................................................................................2 9 
9.1 S TATISTICAL AND ANALYTICAL PLANS ...........................................................................................29 
9.2 S TATISTICAL HYPOTHESES ...........................................................................................................30 
9.3 A NALYSIS DATASETS ...................................................................................................................30 
9.4 D ESCRIPTION OF STATISTICAL METHODS ......................................................................................30  
 9.4.1  General Approach.............................................................................................................30  
 9.4.2  Analysis of the Primary Efficacy Endpoint(s)....................................................................30  
 9.4.3  Analysis of the Secondary Endpoint(s).............................................................................31  
 9.4.4  Safety Analyses................................................................................................................31  
 9.4.5  Adherence and Retention Analyses .................................................................................31  
 9.4.6  Baseline Descriptive Statistics..........................................................................................31  
 9.4.7  Planned Interim Analysis ..................................................................................................31  
Study Number: 18-[ZIP_CODE] Page v 
Version Date: February  19, 20 21 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017   9.4.8  Additional Sub -Group Analyses............................................................. ...........................32  
 9.4.9  Multiple Comparison/Multiplicity .......................................................................................32  
 9.4.10 Tabulation of Individual Response Data...........................................................................32  
 9.4.11 Exploratory Analyses........................................................................................................3 2 
9.5 S AMPLE SIZE........................ .......................................................................................................32 9.6 
MEASURES TO MINIMIZE BIAS.......................................................................................................32  
 9.6.1  Enrollme nt/Randomization/Masking Procedures..............................................................32  
 9.6.2  Evaluation of Success of Blinding.....................................................................................32  
9.6.3 Breaking the Study Bli nd/Participant Code.......................................................................32 10 
SOURCE DOCUMENTS AND ACCESS TO SOURCE DATA/DOCUMENTS .................................32 11
 QUALITY ASSURANCE AND QUALITY 
CONTROL.......................................................................33  
12 ETHICS/PROTECTION OF HUMAN SUBJECTS.............................................................................[ADDRESS_817085] .....................................................................................................33 
12.3 INFORMED CONSENT PROCESS ....................................................................................................34  
 12.3.1  Consent/Assent and Other Informational Documents Provided to Participants................[ADDRESS_817086] of Abbreviations  
AE Adverse Event/Adverse Experience  
AHI Apnea hypopnea index  
ASA24  NCI Automated Self -Administered [ADDRESS_817087]  
CAT Computer Adaptive Testing  
Study Number: 18-[ZIP_CODE] Page vi 
Version Date: February  19, 20 21 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: [ADDRESS_817088]  
ISI Insomnia Severity Index  
MetS  Metabolic Syndrome  
MOP  Manual of Procedures  
N Number (typi[INVESTIGATOR_33891])  
NCI National Cancer Institute  
NIH National Institutes of Health  
NINR  National Institute of Nursing Research  
NYU  [LOCATION_001] University  
OHRP  Office for Human Research Protections  
OSA  Obstructive sleep apnea  
PI [INVESTIGATOR_616318] -Reported Outcomes Measurement Information System  
QC Quality Control  
RA research assistant  
REDCap  Research Electronic Data Capture  
Study Number: 18-[ZIP_CODE] Page vii 
Version Date: February  19, 20 21 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  SAE Serious Adverse Event/Serious Adverse Experience  
SASI  Self-management for Adequate Sleep Intervention  
SDOH  Social Determinants of Health  
SOP  Standard Operating Procedure  
TG Triglycerides  
 
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as authorized  
in writing by [CONTACT_616342]: 18 -[ZIP_CODE]  page 1  
Version Number: September 27, 2019  
Protocol Summary  
Title P20 Extending Sleep to Reverse Metabolic Syndrome in Middle -Aged 
Adults: Acceptability and Feasibility of a Sleep Intervention  
Short Title  P20 Malone Pi[INVESTIGATOR_616319] a sleep extension 
intervention in community -dwelling, short -sleepi[INVESTIGATOR_007], racially/ethnically diverse 
middle -aged adults with MetS. Baseline sleep habits will be assessed and 
used to guide individualized strategies to extend sleep. A [ADDRESS_817089] the efficacy of this 18- week study ([ADDRESS_817090] day of the 12-
week intervention) on sleep duration, MetS risk behaviors (reduced physical 
activity, increased sedentary behavior, poor diet quality), symptoms associated with MetS risk behaviors (poor affective well -being, fatigue), and 
self-regulation. Socio- ecological barriers and facilitators to the intervention 
will be identified using a quantitative and qualitative approach.  
Phase  Pi[INVESTIGATOR_616320] : Test the feasibility and acceptability of a self - 
management for adequate sleep intervention (SASI) in community - 
dwelling, short -sleepi[INVESTIGATOR_007], middle -aged adults with MetS.  
Secondary Objective:  A ssess the preliminary efficacy of SASI on sleep 
duration, MetS risk behaviors (physical activity, sedentary behavior, diet 
quality), symptoms associated with MetS risk behaviors (affective well -
being, fatigue) and self -regulation.  
Exploratory Objective: Explore the perceived barriers and facilitators of SASI 
(e.g., socio -ecological factors) barriers and fac ilitators of SASI (e.g., socio -
ecological factors).  
Methodology  1-group pre -test and post -test pi[INVESTIGATOR_616321] : 1) Acceptability (pre -intervention and post - intervention, 
2) Feasibility (recruitment rate, retention rate, protocol adherence rate).  
Secondary Endpoints : 1) sleep duration, 2) physical symptoms, 3) physical 
activity, 4) sedentary behavior, 5) diet quality, 6) affective well – being, 7) 
self-regulation.  
Study Duration  3 years  
Participant Duration  18 weeks  
Duration of behavioral 
intervention  12 weeks  
Population  Participants will be male and female, 35 -60 year old, short -sleepi[INVESTIGATOR_616322]/ethnic groups with the Metabolic Syndrome in the greater 
[LOCATION_001] City area.  
Study Sites  NYU Langone Health  
NYU Rory Meyers College of Nursing  
 Study Number: 18-[ZIP_CODE] Page 2 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017   
Drug/Device Template Version: 13 JUN 2016  
 
Number of participants  We will screen approximately 220 individuals for a final sample  of N= 60 
participants. Of these 220 participants, we anticipate that 65% will become 
ineligible through the multi -stage screening process and 20% will be lost to 
attrition during the intervention leaving 60 participants with evaluable data.  
Description o f Study 
Intervention/Procedure  SASI is based on Cognitive Behavioral Therapy for Insomnia (CBTI). Like 
CBTI, SASI extends sleep based on sleep efficiency (the proportion of time spent sleepi[INVESTIGATOR_85588] a sleep epi[INVESTIGATOR_1865]). Bedtimes and wake times will be prescr ibed each week for each participant and allow for gradual increases in 
sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains >90%. Earlier bedtimes will extend sleep duration by [CONTACT_616343]. Wake times will not be changed because wake times are often determined by [CONTACT_616344], 
such as work schedules.  
Reference Therapy  Not applicable . 
Key Procedures  Surveys, patient reported outcomes, anthropometric measurements, blood 
pressure measurement, daily sleep diaries, wrist accelerometry, blood draw 
(3 ml CTSI visit 1), open -ended interview . 
Statistical Analysis  Primary endpoints: 1) Acceptability based on the percentage of pre and post 
intervention acceptability surveys with total scores < 21  
(unacceptable), 21 (neutral), greater than 21 (acceptable). 2) Feasibility will be based on recruitment, retention, and study protocol adherence rates.  
  Bellevue Hospi[INVESTIGATOR_307] [ADDRESS_817091], [LOCATION_001], NY [ZIP_CODE] in C/D Building, 
4th Floor [LOCATION_001], NY.  
 Study Number: 18-[ZIP_CODE] Page 3 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  Schematic of Study Design  
 
Screening/  
CTSI Visit 1  
• 
Research Assistants will identify eligible participants through EPIC, Datacore, and other  
recruitment strategies. N= 220 individuals will be screened for inclusion / exclusion criteria  
using a multi -stage screening process that includes 1) a telephone screen, 2) a CTSI visit to  
obtain informed consent, complete screening surveys, and obta in anthropometric and blood  
pressure measurements, 3) a 2 -week baseline data collection to objectively confirm short  
sleep and establish treatment of OSA (at home).  
Baseline data  
collection  
at home  
) 
 ( 
Objectively screen for short sleep  
: Wrist accelerometry and fitbit 24/7 for 14 days, daily sleep diaries.  
 • 
Objectively establish OSA treatment  
: Wear pulse oximeter for 1 -night.  
 :  
 Complete baseline surveys  
Acceptability survey, Composite Scale of Morningness, Economic Vulnerability Survey, Family  
Assessment: General Functioning Scale, Sleepi[INVESTIGATOR_616323], 36 -item Short Form Health  
Survey (SF -36) version 1, ASA24, Demographics -Social Determinan ts of Health (SDOH): Alcohol use  
( 
AUDIT C), Demographics - SDOH: Alcohol Use, Index of Self - regulation, SAFTEE Questionnaire, PROMIS 
Depression 6a.  
Other  
weekly surveys  
: Epworth Sleepi[INVESTIGATOR_7110], PROMIS Fatigue 6a – morning PROMIS 
Fatigue 6a – evening,  
Intervention  
( 
at home  
) 
• 
Sleep diaries (daily), fitbit 24/7, Phone/videoconference calls (weekly with study  
team), Epworth Sleepi[INVESTIGATOR_7110] (weekly), PROMIS Fatigue 6a - morning (weekly) –  
PROMIS Fatigue 6a - evening (weekly).  
Last 2 weeks of  
intervention  
) 
 ( 
at home  
• 
Sleep diaries (daily), Phone calls (weekly with study team), Wrist accelerometry and  
fitbit 24/7 for 14 days, 36 -item Short Form Health Survey (SF -36) version 1, ASA24,  
Demographics - SDOH: Alcohol use (AUDIT C), Demographics - SDOH: Alcohol Use,  
Index of Self -regulation, SAFTEE Questionnaire; PROMIS Depression 6a. Other weekly  
survey s: PROMIS  
Fatigue 6a – morning, PROMIS Fatigue 6a –evening, Epworth  
Sleepi[INVESTIGATOR_7110].  
Final Visit  
( 
at home  
) 
• 
Acceptability survey.  
• 
Open -ended Interview  
. 
 Study Number: 18-[ZIP_CODE] Page 4 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: [ADDRESS_817092] 
[LOCATION_001], [LOCATION_001] [ZIP_CODE]  
[PHONE_12748] [EMAIL_11723] 
Principal Investigator: [INVESTIGATOR_124]. Malone will direct and oversee all aspects of the pi[INVESTIGATOR_799], ensuring that study 
procedures are implemented and maintained for the enrollment of participants, form development, collection 
of data, data management, and budget maintenance. She will have primary responsibility for oversight of 
data analysis, preparation of manuscripts, and the submission of annual and final reports.  
Azizi Seixas, PhD, Assistant Professor  
NYU School of Medicine Department of Population  
Health [ADDRESS_817093]  
[LOCATION_001], [LOCATION_001] [ZIP_CODE]  
[PHONE_12749] [EMAIL_11724]  
Co-investigator: [CONTACT_616388] is well experienced leading funded projects related to sleep, cardio- metabolic 
health and racial/ethnic disparities. [CONTACT_616388] has worked as a project manager on several NIH -funded sleep-
related studies including a NIMHD -funded R01 study on sleep obstructive sleep apnea among Blacks and as  
a principal investigator [INVESTIGATOR_2394] a NIH -funded K01 award investigating the relationship between insufficient sleep 
and cardiovascular disease markers between Blacks and Whites. [CONTACT_616388]’ expertise will also be brought to 
bear on recruiting community participants and identifying barriers to extending sleep across diverse subgroups. [CONTACT_616388] will contribute to the dissemination of study findings.  
Victoria Vaughan Dickson, PhD, RN, Associate Professor, 
NYU Rory Meyers College of Nursing  
[ADDRESS_817094] 
[LOCATION_001] , [LOCATION_001] [ZIP_CODE]  
[PHONE_12750] [EMAIL_11725] 
Co-investigator: [CONTACT_496304] is an Associate Professor in the NYU Rory Meyers College of Nursing, Director 
of the Pless Center for Nursing Research, program director of the NYU Meyers NIOSH -funded T42 Program  
in Occupational and Environmental Health Nursing, and co -director of the NIH -funded NYU School of Medicine 
CTSA Scholars Program. [CONTACT_496304]’s work has led to an improved understanding of the socio- cultural 
influences of self -care among women and racial /ethnic minority groups and the development of innovative 
theory based interventions. This expertise will be brought to bear on our proposed CTSI pi[INVESTIGATOR_16080]. [CONTACT_616389] is also an international expert in qualitative research techniques and mixed methods research. She 
will provide expertise for the qualitative design and analysis where we will identify barriers and facilitators to 
the sleep intervention. [CONTACT_496304] will play a critical role in identifying and recruiting potential participants. The overarching goal of his research is to address patient - level, provider -level, and system -level barriers hindering 
adoption of healthful practices.  
Girardin Jean- Louis  
Professor of Population Health and Psychiatry  
Center for Healthful Behavior Change  
Department of Population Health  
[LOCATION_001] University School of Medicine  
[ADDRESS_817095], 6th Floor  
[LOCATION_001], NY [ZIP_CODE]  
[PHONE_12746] 
Girardin.Jean- [EMAIL_11726]  
 Study Number: 18-[ZIP_CODE] Page 5 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  Co-investigator: [CONTACT_616390] is Professor of Population Health and Psychiatry at NYU Langone Health. He is 
Director of the NHLBI -funded PRIDE Summer Institute on Behavioral Medicine and Sleep Disorders Training 
Institute and Director of the T32 Program on Translational Behavioral Cardiovascular Health Research. He 
served for three years on the NHLBI’s Sleep Disorders Research Advisory Board, and for four years as a member 
of the Cancer, Heart, and Sleep Epi[INVESTIGATOR_623] (CHSB) study section, and the NHLBI Special Emphasis 
Panel/Scientific Review Group. As PI [INVESTIGATOR_616324], [CONTACT_616390] w ill play a critical role in recruiting 
potential participants and provide expertise in the proposed sleep intervention.  
Gary Yu, PhD  
NYU Rory Meyers College of Nursing  
[ADDRESS_817096] 
[LOCATION_001], [LOCATION_001] [ZIP_CODE]  
212 998- 5486 [EMAIL_11729]  
Biostatistician: Dr. Y u is a biostatistician trained at Columbia’s Mailman School of Public Health. His dissertation 
involved creating a new dimensional -informative mixture model (DIMM) [NIH/NHLBI R01HL111195], a model -
based clustering technique to create endophenotypes of major chronic conditions (MCC) (i.e. pain, fatigue, 
depression, CVD) under conditions of severe disease heterogeneity in the clinical diagnosis.   [CONTACT_20266] has applied 
a variety of advanced analysis approaches to complex longitudinal data including multiple imputation for missing data, structural equation modeling, generalized estimating equations, and linear and generalized linear mixed models. His expertise as a biostatistician will be brought to bear on the quantitative analyses of the proposed 
study aims and complement the qualitative analyses exploring the individual, family, and community factors 
influencing sleep extension. His work addressing barriers to racial/ethnic minorities for participating in research 
studies will inform the study design and analysis . 
Bradley Aouizerat, PhD  
Bluestone Center for Clinical Research  
[ADDRESS_817097], Room 1024S, [LOCATION_001], NY [ZIP_CODE]  
[LOCATION_001], [LOCATION_001] [ZIP_CODE]  
212 998- 9167 [EMAIL_11728] 
Fay Wright PhD, APRN -BC  
Assistant Professor  
NYU Rory Meyers College of Nursing  
[ADDRESS_817098] 
[LOCATION_001], [LOCATION_001] [ZIP_CODE]  
[PHONE_12751] [EMAIL_11730] 
Key Collaborator: [CONTACT_150547] is Assistant Professor at the NYU Rory Meyers College of Nursing. Her expertise 
in fatigue research will be brought to bear on the analyses of these data. [CONTACT_616391] ght will also assist in identifying 
and recruiting potential participants.  
Gail Melkus, PhD, RN, Professor & Associate Dean for Research  
NYU Rory Meyers College of Nursing  
[ADDRESS_817099] 
[LOCATION_001], [LOCATION_001] [ZIP_CODE]  
[PHONE_12752] [EMAIL_6033] 
Key Collaborator: [CONTACT_306291] is the Florence and William Downs Professor in Nursing Research, Associate 
Dean for Research, and Director of the Muriel and Virginia Pless Center for Nursing Research. Her expertise 
in conducting behavioral intervention research and serving as a career development mentor to many rising 
early -career scientists will benefit [CONTACT_616392] in the conduct of this pi[INVESTIGATOR_799].  
Laura Prescott  
P20 Program Manager  
NYU Rory Meyers College of Nursing  
[ADDRESS_817100] 
 Study Number: 18-[ZIP_CODE] Page 6 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  [LOCATION_001], [LOCATION_001] [ZIP_CODE]  
[PHONE_12753] [EMAIL_11731] 
Agnes Wong, MA  
Pi[INVESTIGATOR_616325]  
[ADDRESS_817101] 
[LOCATION_001], [LOCATION_001] [ZIP_CODE] [EMAIL_11732]  
Franklin Zizi  
Assistant Research Scientist  
NYU Rory Meyers College of Nursing Franklin.Zizi@nyulangone .org 
Amy Warner, MSN, FNP -C  
Research Assistant  
NYU Rory Meyers College of Nursing [EMAIL_11733]  
Lauren Ghazal, MS, FNP -BC  
Research  Assistant  
NYU Rory Meyers College of Nursing [EMAIL_11734] 
Nicole B. Perez, MSN, ARNP, PMHNP -BC 
Research Assistant  
NYU Rory Meyers College of Nursing [EMAIL_11735] 
 
Clinical and Translational Science Institute, Bellevue Hospi[INVESTIGATOR_307]  
[ADDRESS_817102], [LOCATION_001], NY [ZIP_CODE] in C/D Building, 4th Floor [LOCATION_001], NY 
[EMAIL_11736] 
One outpatient visit will take place at this site the remainder of the study will take place in the home environment   
 Study Number: 18-[ZIP_CODE] Page 7 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  1 Introduction, Background Information and Scientific Rationale  
1.1 Background Information and Relevant Literature  
Name [CONTACT_616387]. The Self -management for Adequate Sleep Intervention (SASI) 
is a 12- week self -management for adequate sleep intervention (SASI) that extends sleep gradually based on 
individual responses to the intervention. Participants will be enrolled in the study for [ADDRESS_817103] day of the intervention. SASI is based on Cognitive Behavioral Therapy for Insomnia (CBTI). Like CBTI, SASI extends sleep based on sleep efficiency (the 
proportion of time spent sleepi[INVESTIGATOR_85588] a sleep epi[INVESTIGATOR_1865]). Bed times and wake times will be prescribed each 
week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes 
earlier each week provided sleep efficiency remains >90%. Earlier bedtimes will extend sleep duration by 
[CONTACT_616343]. Wake times will not be changed because wake times are often 
determined by [CONTACT_616344], such as work schedules.  
Summary of relevant clinical research. Diet and exercise are the first line of treatment for effectively reducing 
the Metabolic Syndrome (MetS)1. However, disappointing outcomes are reported when diet and exercise 
programs are translated into less intense, more affordable community based programs. Less intense programs report only half the amount of weight loss achieved by [CONTACT_616345]
2. Moreover, only 50% of 
Americans with elevated glucose levels attempt modifying their diets and physical activity3. Poor participation 
rates suggest that diet and exercise are only effective for select, highly motivated individuals4. Extending sleep 
is an innovative approach to reducing MetS because it shifts the first line of treatment from diet and exercise alone to include sleep, a potentially modifiable, upstream factor for MetS.  
Discussion of important literature and data that are relevant to the t r
 ial and that provide background for  the trial. 
Applicable clinical, epi[INVESTIGATOR_904], or public health background or context of the study. Short sleep, defined as 
≤ 6 hours/night5, is strongly associated with MetS6, a cluster of risk factors that profoundly increases the risk for 
multiple chronic conditions such as type [ADDRESS_817104] prevalence of short sleep (~30%) is reported 
by [CONTACT_361641] -aged adults (35- 60 years old)8. Extending sleep in short sleepers without MetS improves behavioral 
and clini cal risk factors, as it reduces hedonic food cravings9 and improves insulin sensitivity and blood 
pressure10,11. Average 24 -hour systolic and diastolic blood pressures are reduced by 14mmHG and 8mmHG, 
respectively, following sleep extension11. Progress in extending sleep interventions to persons with MetS is 
limited by [CONTACT_616346] - dwelling, racially/ethnically diverse, middle- aged 
adults with MetS. The extent to which this high risk, understudied group can extend sleep and the contextual factors influencing their ability to do so are not known. Also unknown is whether extending sleep improves symptoms, such as poor affective well -being and fatigue, that are associated with MetS risk behaviors
12,13. 
Short sleep may direct l y impact MetS, a chronic inflammatory state14, by [CONTACT_616347].  
Elevated C -reactive protein has been found in habitual short sleepers15. Short sleep may also impact MetS 
through its effect on MetS risk behaviors16-18. Reduced physical activity, increased sedentary behavior, and 
unhealthy diets are associated with habitual short sleep19,20. Sleep deprivation symptoms, such as poor 
affective well -being and fatigue21, further increase MetS risk behaviors12,13. Finally, short sleep impairs 
executive functioning22, such as self -regulatory capacities that are important for adopting and sustaining 
healthy behaviors23. 
Importance of the study and any relevant treatment issues or controversies. Critical barriers exist to using sleep 
interventions to address MetS. First, laboratory findings may not translate to the context of people's real lives. Community -based interventions are needed to draw conclusions about the effects of sleep extension on MetS. 
For example, a 3- week community -based sleep restriction  study reported increased insulin resistance after 1 
week, corroborating laboratory evidence
24, but reduced insulin resistance during the remaining weeks25, 
contradicting laboratory evidence. This exemplifies a shortcoming of lab studies and the profound i mplications 
for treatment interventions. Second, racial/ethnic minorities are under -represented in extant sleep extension 
studies. Yet, Black adults are more likely to be short sleepers26 and are more vulnerable to the adverse effects 
of short sleep27. Third, socio -ecological factors at the individual (e.g., gender)28, microsystem (e.g., family 
support)29, and exosystem (neighborhood conditions)[ADDRESS_817105] relied on generic approaches advising individuals to sleep more. These recommendations lack 
 Study Number: 18-[ZIP_CODE] Page 8 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  the precision needed to be effective in diverse populations because they do not account for individual variability 
in lifestyle. Additionally, these recommendations do not address how to extend sleep.  
This proposed study is significant because it will determine the acceptability and feasibility of a sleep 
intervention in an understudied population: racially/ethnically diverse middle- aged adults with MetS. The 
preliminary evidence of the effectiveness of thi s intervention will translate laboratory evidence suggesting that 
sleep can improve metabolic health into a promising new treatment for individuals with MetS, a group at high 
risk for multiple chronic conditions in later life. The socio- ecological factors identified will contribute to targeting 
and tailoring future sleep interventions in high- risk, understudied groups. The preliminary data generated will 
be used to test this intervention in a fully powered randomized control trial. Without personalized strategies to reduce MetS severity in middle age, healthy aging will be thwarted by a higher and lengthier burden of multiple chronic conditions in later life.  
1.2 Rationale  
State the problem or question under study (e.g., describe the disease and current limi tations of knowledge  or 
therapy). Include a statement of the hypothesis. Progress in extending sleep extension interventions to persons 
with MetS is limited by [CONTACT_616346] - dwelling, racially/ethnically diverse, 
middle -aged adults with MetS. The extent to which racially/ethnically diverse middle- aged adults with MetS can 
extend sleep and the contextual factors influencing their ability to do so are not known. Also unknown is whether extending sleep improves symptoms, such as poor affective well -being and fatigue, that are 
associated with MetS risk behaviors
12,13. In this study, we will: 1)  Test the feasibility and acceptability of a 
self-management for adequate sleep intervention (SASI) in community -dwelling, short -sleepi [INVESTIGATOR_007], middle -aged 
adults with MetS.  
2) A ssess the preliminary efficacy of SASI on sleep duration, MetS risk behaviors (physical activity, 
sedentary behavior, diet quality), symptoms associated with MetS risk behaviors (affective well -being, 
fatigue) and self - regulation.  
3) Explore the perceived barriers and facilitators of SASI (e.g., socio- ecologicalfactors).  
Justification for the method of administration, treatment regimen of the intervention, intervention periods, 
and selection of study population. The method o f administration, SASI, is based on Cognitive Behavioral 
Therapy for Insomnia (CBTI). SASI differs from CBTI because the first step of sleep restriction prescribed by [CONTACT_616348]. This is because the participants have already been verified as short - sleepers. 
However, SASI does employ CBTI’s gradual approach for increasing sleep time and applies it to short 
sleepers. CBTI has demonstrated effectiveness in improving sleep in persons with insomnia
31,32. 
Increasing sleep duration gradually has also been demonstrated to sustain sleep quality. The 12- w eek 
intervention period of gradually increasing sleep duration by [CONTACT_616349] 15 minutes per week (or 1 hour per month) will provide the time needed to increase sleep duration in habitual 5 hour sleepers to the 
recommended 7 to 8- hour sleep duration. Our preliminary data from an 8- week sleep extension intervention 
increased sleep duration up to 2 hours over 8 weeks using this approach (Grandner, unpublished data). Moreover, 12 weeks will provide preliminary data regarding adaptation to adequate sleep duration (7- 8 
hours) and the effects of the sleep intervention on key biomarkers that may be missed by [CONTACT_616350], such as improved triglyceride and HDL- c measures. The study population selected 
was middle -aged adults with MetS because short sleep has been associated with MetS. Plausible biological 
and behavioral pathways have been demonstrated  
and further support a relationship between MetS and short sleep
10. Middle -aged adults were chosen for this 
pi[INVESTIGATOR_616326]- aged adults than other stages of adulthood12. 
Discuss known or potential problems associated with the control group chosen in light of the specific  d isease 
and therapi[INVESTIGATOR_616327] s tudied. There is no control group. This is a one group pre- and post - intervention study 
design that will provide preliminary data for a fully powered R01 randomized controlled trial.  
 Study Number: 18-[ZIP_CODE] Page 9 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  1.3 Potential Risks & Benefits  
1.3.[ADDRESS_817106] the 
potential participant’s medical care.  
Loss of confidentiality . To protect against loss of confidentiality all survey data and clinical assessment data 
will be entered directly into REDCap (Research Electronic Data Capture). REDCap is a secure, web -based 
application designed to support data capture and storage for research studies, providing 1) an intuitive interface for validated data entry; 2) audit trails for tracking data manipulation and export procedures; 3) automated export procedures for seamless data downloads to common statistical packages; and 4) procedures for importing data from external sources. REDCap has been designed to allow for compliance 
with such standards as HIPAA, [ADDRESS_817107] discomfort associated with the accelerometer, participants will be instructed in 
person during their CTSI intake visit on the use of these devices. Participants will be given verbal as well as 
written, illustrated instructions for using the devices. Study team 24/[ADDRESS_817108] by [CONTACT_616351]. Careful monitoring of sleep efficiency and excessive 
sleepi[INVESTIGATOR_616328]. The treatment for insomnia 
on which SASI is based (Sleep Restriction Therapy) can produce sleepi[INVESTIGATOR_008], especially in the initial weeks of treatment. The proposed intervention, though, does not begin with a curtailment of sleep opportunity, so these 
issues should not be present. Sleep will be extended gradually and on an individual basis using the results 
from the previous week’s sleep diary data
. Participants diagnosed with an ARES score of greater than or 
equal to six suggesting OSA will be referred to the Sleep Disorders Center at NYU Langone Health for further 
evaluation and treatment.  
Blood drawing risks. The risk of blood specimen collection is within the routine of clinical care. To protect 
against potential risks associated with the blood draw such as dizziness, decreased alertness, and symptoms associated with low blood sugar, every effort will be made to schedule the C TSI appointment between [ADDRESS_817109] techniques at the NYU CTSI will be used for analysis of the blood samples according to CLIA 
standards. Approximately 3 ml of blood will be drawn (as  needed to objectively confirm MetS) during CTSI visit 
1. 
Inconvenience. To minimize the most likely risk of inconvenience, the following steps will be undertaken to 
reduce burden. Short forms of the surveys will be used wherever appropriate.  
Embarrassment. To minimize embarrassment that may be associated with survey questions and waist 
measurements, we have selected survey questions that have been established and used in previous research 
studies. Waist circumference is a routine measurement taken in health care settings for persons with MetS. To 
protect against embarrassment participants will be free to omit answers and or refuse waist measurements. 
Additionally, waists will be measured in a private exam room. Clinicians sensitive to emotional  or physical 
 Study Number: 18-[ZIP_CODE] Page 10 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: [ADDRESS_817110] these interviews and examinations. Participants who are 
psychologically distressed will be referred for appropriate treatment.  
Rationale for the necessity of exposing human participants to such risks.  T here is a critical need to develop 
personalized strategies to reverse MetS in middle- aged adults. Without such strategies to reduce MetS severity 
in middle age, healthy aging will be thwarted by a higher and lengthier burden of multiple chronic conditions in later life.  
Why the value of the information to be gained outweighs the risks involved.  
 These data will provide a more 
complete understanding of the association between sleep and MetS. This study will determine the acceptability and effectiveness of e xtending sleep in a high- risk, understudied group: racially/ethnically diverse, short -
sleepi[INVESTIGATOR_616329]. The socio- ecological factors identified will contribute to targeting and 
tailoring future sleep interventions in high risk, understudied groups.  
If risk is related to proposed procedures included in protocol, any alternative procedures that have been 
considered and an explanation on why alternative procedures were not included. Risk associated with the 
procedures in this protocol are minimal. Participation in this study is voluntary and separate from medical care; therefore, patients enrolled will be informed verbally and in writing that they may withdraw at any time without 
giving reason and without penalty.  
1.3.[ADDRESS_817111] the feasibility and acceptability of a self -management for adequate sleep intervention (SASI) in 
community -dwelling, short -sleepi[INVESTIGATOR_007], middle -aged adults with MetS.  
2.2 Secondary Objectives (if applicable)  
The secondary objectives are to compare differences between pre- and post-intervention sleep duration, 
MetS risk behaviors (physical activity, sedentary behavior, diet quality), symptoms associated with MetS risk 
behaviors (affective well -being, fatigue) and self -regulation. We will also explore the perceived barriers and 
facilitators of SASI (e.g., socio -ecological factors).  
[ADDRESS_817112] the acceptability and feasibility of the Self - management for 
Adequate Sleep Intervention (SASI) in racially/ethnically diverse middle- aged adults with MetS.  
This is an 18- week study. In the first 2 weeks, baseline data will be collected. During week 3, the baseline data 
will be used to confirm study eligibility based on objectively estimated short sleep and to plan the personalized 
intervention. During weeks 4 to 15, the study team will call or videoconference participants once a week to 
prescribe a sleep schedule based on their daily sleep diaries. At the end of week 15, participants will be asked to schedule their final visit within 3 weeks.  
 Study Number: 18-[ZIP_CODE] Page 11 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  Acceptability data will be collected at two time points (i.e., pre- intervention and at the final visit). The final visit 
will include a [ADDRESS_817113] the acceptability and feasibility of SASI. The primary endpoint, acceptability, 
will be evaluated by [CONTACT_616352] (overall acceptability survey 
scores greater than 21), neutral (overall acceptability survey scores equal to 21), and unacceptable (overall 
acceptability survey scores less than 21) at each of two time points (pre- intervention and post intervention). 
The feasibility endpoints will be determined by [CONTACT_941] 1) recruitment rate: the percentage of potential participants 
screened in order to enroll 60 participants 2) attrition rate: the percentage of enrolled participants completing 
the 18- week study. Participants will be considered withdrawn after 4 weeks of not responding to phone 
calls/emails during the intervention and the 3) protocol adherence rates: the percentage of participants 
completing greater than or equal to 4 daily sleep diary entries per week for 80% or more of the intervention 
period.  
3.2.[ADDRESS_817114] intervention interviews will be conducted. Identifying perceived 
barriers and facilitators will lead to future tailoring and/or targeting of SASI.  
4 Study Enrollment and Withdrawal  
To reach a final sample of N= 60, we will recruit 220 individuals. Of these, we anticipate that 65% will become 
ineligible through the multi -stage screening process and 20% will be lost to attrition during the intervention 
leaving [ADDRESS_817115] meet all of the following criteria:  
1. G reater than or equal to [ADDRESS_817116] prevalence of short sleep compared to other stages of adulthood8,34. 
2. Objectively confirmed MetS factors defined by [CONTACT_10980]: a) waist 
circumference greater than 120cm (men) or 88cm (women), b) blood pressure greater than or 
equal to 135 mmHg systolic or greater than or equal to 85 mmHg diastolic or antihypertensive 
medication use, c) fasting glucose greater than or equal to 110 mg/dL or insulin or oral 
hypoglycemic medication use, d) serum triglycerides greater than or equal to 150mg/dL or 
hypertri glyceride medication use, e) HDL- c less than 40mg/dL (women) or less than 50 mg/dL 
(men) or medication use for low HDL-c1. MetS was selected because individuals with MetS are 
at high risk for multiple chronic conditions35. 
 Study Number: 18-[ZIP_CODE] Page 12 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  3. A ccelerometry confirmed short sle ep (average work day sleep less than or equal to 6 
hours/night). Self -reported sleep may overestimate sleep duration. This will ensure that 
participants will have short sleep patterns that are associated with MetS outcomes.  
4. English speaking . Participants w ill need to demonstrate adequate English comprehension 
(assessed during informed consent).  
4.2 Exclusion Criteria  
An individual who meets any of the following criteria will be excluded from participation in this study:  
1. P regnancy/lactation (self-reported). Pregnancy and lactation can disrupt habitual sleep patterns, 
and hormonal changes during pregnancy increase insulin resistance and may confound MetS37. 
2. Current chemotherapy treatments (self -r eported). Current chemotherapy treatments may 
contribute to fatig ue and sleep disturbances38. 
3. Alcohol abuse w ill be assessed with the Alcohol Use Disorders Identification Test (a measure 
that has demonstrated good reliability and validity). Alcohol abuse/dependence may contribute 
to sleep disturbances and limit the participant’s ability to take part in sleep interventions39. 
Individuals with scores > 15 (men) or > 13 (women) will be excluded.  
4. Night shift or shift work (previous 2 months), trans -m eridian travel (previous 4 weeks), or 
planned shift work or trans -meridian travel during intervention period (self -reported). These will 
be to ensure that sleep estimates from baseline represent participants’ habitual sleep and to 
ensure adherence with the sleep intervention.  
5. Moderate- s evere or severe depression will be assessed w ith the Patient Health Questionnaire 
(PHQ -9). The PHQ -[ADDRESS_817117] and criterion validity 
(Kroenke et al, 2001). Using professional interviews as the criterion standard, a PHQ -9 score of 
10 had a sensitivity of 88% and a specificity of 88% for detecting major depression. It has been 
validated in clinical populations and been used in a large number of cardiovascular studies. 
Moderate- severe depression or severe depression may contribute to sleep disturbances40 and 
interf ere with the participant’s ability to adhere to the sleep interventions. Therefore, individuals 
with scores ≥ 15 will be excluded.  
6. Chronic use of sleep -p romoting medications (self -reported) defined as taking a sleep -promoting 
medication ≥ 3 nights per week . These may interfere with sleep patterns and limit the 
participant’s ability to take part in the sleep interventions.  
7. Habitual nappi[INVESTIGATOR_007], d efined as 2 naps per day or > 90 minutes of nappi[INVESTIGATOR_54139] 3 or more days of 
the week will be assessed during baseline wit h accelerometry. This will be to ensure adherence 
with the sleep intervention.  
8. Untreated OSA, defined by [CONTACT_616353] (AHI)> 10 using the hypopnea scoring 
criteria of a 4% or more oxyhemoglobin saturation. This criterion has been used because of  its 
independent association with cardiovascular disease (Punjabi et al 2008, Punjabi et al 2013).  
9. Any condition that, in opi[INVESTIGATOR_17439], will interfere with the safe completion of the study.  
4.3 Vulnerable Subjects  
No special classes of people who may  be considered vulnerable populations (e.g., fetuses, neonates, pregnant 
women, children less than 16 years of age, prisoners, institutionalized individuals) will be recruited into the study.  
4.4 Strategies for Recruitment and Retention  
Recruitment . Recruitment strategies will include 1) electronically posting IRB -approved flyers at NYULH, NYU 
College of Dentistry, NYU College of Nursing, Seastreak commuter ferries and ferry terminals, and metro 
terminals, 2) advertising in the community so interested  individuals can contact [CONTACT_3476], 3) 
posting/distributing IRB -approved flyers in the community and in clinics, 4) contact[CONTACT_616354]- I’s past study 
participants who agreed to be contact[CONTACT_94092], 5) using Epic to identify potential participants (see section below on using DataCore for recruitment/identification purposes, and 6) sending IRB -
approved study recruitment messages to potential study volunteers using research registries such as Research Match. Subject identification and recruitment are described in detail below.  
 Study Number: 18-[ZIP_CODE] Page 13 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  Retention. We will offer an incentive for completing each of the study visits, as well as for completing 
6 weeks of the SASI intervention (Total incentive: $100). Multiple means of contact [CONTACT_616355], including email, mailing address, and phone number. Reminders for study 
visits will be sent via email, if available, or via one of the other means of contact.  
4.4.[ADDRESS_817118] information.  
4.4.2  Advertising in the community  
Community members may learn of the study through electronically -posted flyers (see Section 4.4.1), or other methods, such 
as radio talk shows (e.g. NYU Langone Nurse Radio, sleep apnea support groups). Interested community members may contact [CONTACT_616356]. After contact[CONTACT_616357], the RA will provide individuals with the option of proceeding with the IRB -approved verbal telephone consent and screening.  
4.4.3  Posted/distributed flyers 
Flyers promoting the study will be available to individuals who v isit the participating health facilities (see Section 4.4.4 NYU 
Langone Health Recruitment for more detailed information). Flyers will also be distributed at community sites so that 
interested individuals can contact [CONTACT_3476]. Those responding to the  distributed flyer will be contact[CONTACT_616358] -approved verbal telephone consent and screening.  
4.4.4  NYU Langone Health recruitment  
This study will recruit individuals from settings affiliated with NYU Langone Health, such as employee health, occupational 
medicine, cardiology, endocrinology, and college of nursing faculty practices. Flyers promoting this study will be available to 
individuals who visit the participating health facilities or attend emp loyee health events (e.g. flu shot clinics, health fairs). 
Clinical staff informed of the study protocol and provided with the IRB -approved study information may also inform individuals 
about the study and refer them to the study team to contact [CONTACT_616359]. With approval of the clinic 
site, the research staff will also be available at the clinic site during specific hours to facilitate recruitment.  
4.4.[ADDRESS_817119] study participants from the Co- I’s pr evious studies who agreed to be contact[CONTACT_616360]. Contact[CONTACT_616361] -
approved verbal telephone consent and screening.  
4.4.6  Use of DataCore/Epic Information for Recruitment Purposes 
A study team member will submit a request to DataCore to identify potential participants. Data points to be 
searched will include age, blood pressure measurements, fasting glucose, serum trigl ycerides, HDL -c, 
medication use (antihypertensives, insulin, oral hypoglycemic, hypertriglyceridia medication, or medication 
use for low HDL- c) within the last [ADDRESS_817120] a report from EPIC for 
these patients with identifiable protected health information (name, email address) for research related 
purposed. Only study team members with Epic access will have access to the search results.  
The Epic team will set up a recruitment message in MyChart and work with the PI [INVESTIGATOR_616330]. The IRB -approved MyChart recruitment message is attached. The text will include a description 
of the study, inclusion and exclusion criteria, and contact [CONTACT_71722] (phone number and email). 
The recruitment message may be repeated two times at two- month intervals if needed for subject recruitment 
(total 3 Epic MyChart messages).  
These data will be used solely for participant identification in order to determine patients who are initially 
eligible and for chart review (previous 12- month blood specimen results from Co- investigator’s study). The 
study team will discard information from those who do not wish t o participate in the study. If a subject 
requests information regarding opting out of further recruitment for all research, subjects will be directed to 
 Study Number: 18-[ZIP_CODE] Page 14 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: [ADDRESS_817121] - [EMAIL_2365] or 1- 855-777-
7858.  
4.4.7 Research Match  
We will also utilize Research Match (ResearchMatch.org), a national, electronic, web -based  
recruitment tool that was created through the Clinical and Translational Science Awards Consortium in 2009 
to send study recruitment messages to potential study participants. This study’s recruitment content will be 
inserted into the standard Research Match electronic notification that informs possible matched participants 
that they have been identified as a potential match for this study. The Research match recruitment message is attached. The secure Research Match clearinghouse will route this standard Research Match notification 
to each of these Research Match participants. These potentially matching participants will have the option 
of replying “yes”, “no”, or “not respond” through a set of quick links available in this notification of the study announcement. The contact [CONTACT_194090] “yes” responding participants will be made available on the PI’s “Manage my Study” dashboard. A member of the research team will contact [CONTACT_616362]/telephone consent and screening or an in- person 
meeting. If a subject requests information regarding opting out of further recruitment for all research, 
subjects will be directed to contact [CONTACT_616363]- contact -
[EMAIL_2365] or 1- 855-777- 7858.  
4.[ADDRESS_817122] 2 weeks of 
baseline data collected during the participant’s everyday routine, a third week to evaluate the sleep baseline 
data to confirm short sleep using the accelerometry data and to plan the personalized intervention, week s 4-[ADDRESS_817123]. An investigator may 
terminate participation in the study if:  
• Any clinical adverse event (AE), laboratory abnormality, or other medical condition or situation occurs 
such that continued participation in the study would not be in the best interest of the participant  
• The participant meets an exclusion criterion (either newly developed or not previously recognized) 
that precludes further study participation.  
• The participant does not respond to phone calls/emails for [ADDRESS_817124] safety and efficacy data after withdrawal.  
Any data collected before withdrawal from the study will be retained for analysis, and no new data will be 
collected. If the participant requests that data be destroyed, all paper records will be shredded, and any data 
already processed into computer files will be removed. However, if results based on the participant's data 
have been submitted for publication or presentation before the request is made, the results cannot be 
removed from the publication or presentation.  
4.5.3 Premature Termination or Suspension of Study  
This study may be temporarily suspended or prematurely terminated if there is sufficient reasonable cause. 
Written notification, documenting the reason for study suspension or termination, will be provided by [CONTACT_616364] [INVESTIGATOR_616331], and [LOCATION_001] University IRB. 
If the study is prematurely terminated or suspended, the PI [INVESTIGATOR_33894](s) for the termination or su spension. As this study will evaluate acceptability, feasibility, and 
preliminary efficacy, it will not be possible to determine whether the intervention is efficacious or futile for the 
population studies. Circumstances that may warrant termination or sus pension include, but are not limited 
to: 
 Study Number: 18-[ZIP_CODE] Page 15 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  • Determination of unexpected, significant, or unacceptable risk to participants  
• Insufficient compliance to protocol requirements  
• Data that are not sufficiently complete and/or evaluable  
If the study is temporarily suspended, the study may resume once concerns about safety, protocol compliance, 
data quality is addressed and satisfy the sponsor and/or IRB.  
5 Behavioral/Social Intervention  
5.1 Study Behavioral or Social Intervention(s) Description  
SASI, is based on Cognitive Behavioral Therapy for Insomnia (CBTI). SASI differs from CBTI because the first 
step of sleep restriction prescribed by [CONTACT_616348]. This is because the participants have already 
been verified as short -sleepers. However, SASI does employ CBTI’s gradual approach for increasing sleep 
time and applies it to short sleepers. The 12 -week intervention period of gradually increasing sleep duration by 
[CONTACT_616349] 15 minutes per week (or 1 hour per month) will provide the time needed to increase sleep 
duration in habitual 5 hour sleepers to the recommended 7 to 8 hour sleep duration. Like CBTI, SASI extends 
sleep duration based on sleep efficiency (the proportion of time spent sleepi[INVESTIGATOR_85588] a sleep epi[INVESTIGATOR_1865]). Bed 
times and wake times will be prescribed each week for each participant and allow for gradual increases in sleep opportunity. Bedtimes will be set 15 minutes earlier each week provided sleep efficiency remains >90%. Earlier betimes will extend sleep duration by [CONTACT_616343]. Wake times will not be 
changed because wake times are often determined by [CONTACT_616344], such as work schedules. There will be no control intervention in this pi[INVESTIGATOR_799].  
5.1.[ADDRESS_817125] of 
approximately 15 to 30 -minute phone calls or NYU WebEx videoconferencing based on the participant’s 
preference. During these individual weekly sessions, the participant and the study team member will review 
the participant’s previous week’s consensus sleep diary, discuss challenges implementing the sleep 
intervention, and determine the work day bedtime- wake time schedule for the upcoming week. Daily text 
message or email reminder s will be sent to participants to complete their daily sleep diary as needed.  
5.1.[ADDRESS_817126]. Dickson, Co- investigator. Barriers to implementing SASI 
will be identified and resolved together with the participant and the  PI [INVESTIGATOR_12749]- I’s. 
5.1.[ADDRESS_817127] Compliance with Study Intervention  
The study team will track feasibility data, including completion of daily sleep diaries and retention rates. 
Participant engagement will be assessed through attendance records for weekly sessions and by [CONTACT_616365]. Daily texts or email reminders will be sent to participants to remind them 
to complete the diary as needed.  
 Study Number: 18-[ZIP_CODE] Page 16 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  6 Study Procedures and Schedule  
6.1 Study Procedures/Evaluations  
6.1.1  Study Specific Procedures 
Participants meeting the telephone screen eligibility criteria will be invited to the CTSI for an intake visit 
(CTSI visit 1). The enrollment procedures at the CTSI visit 1 will include the 1) informed consent process, 
2) further screening for eligibility using surveys, and 3) further screening to objectively confirm MetS 
(anthropometric measurements and 3 ml. blood draw if needed for glucose and lipi[INVESTIGATOR_805]). (Participants will 
have the option of providing an optional 8ml blood sample for blood storage.).  
Assessments will be done at the following time points: 1) CTSI visit 1, 2) during 2- week baseline assessment 
at home, 3) during the last 2- weeks of the intervention, and 4) within three weeks of completing the 
intervention (Final visit  – at home).  
The screening surveys, physical exam, and blood draw will be completed at the CTSI at Bellevue Hospi[INVESTIGATOR_307] [ADDRESS_817128], [LOCATION_001], NY [ZIP_CODE] in C/D Building, 4th Floor [LOCATION_001], NY. About 220 subjects will be in the study. Accelerometry, pulse oximetry (as needed), acceptability (pre- and post - intervention), Composite Scale 
of Morningness, Economic Vulnerability Survey, Family Assessment Device – General Functioning Scale, 36-
item Short Form Health Survey (SF -36) version 1, ASA24, Demographics - SDOH: Alcohol use (AUDIT C), 
Demographics – SDOH: Tobacco use, Index of Self - regulation, SAFTEE questionnaire, Sleepi[INVESTIGATOR_616332], PROMIS Fatigue 6a –morning, PROMIS Fatigue 6a – evening, Epworth Sleepi[INVESTIGATOR_7110], Daily sleep 
diaries, acceptabili ty survey (post - intervention), and the open -ended interview will take place at home.  
Demographic and Clinical Characteristics.  
• Demographic:  
o BRICS NINR Demographic Data Elements o BRICS NINR 
Demographics (with race clarifying questions)  
o BRICS Demographics - Diagnosis  
• General health questions (self -reported) o Pregnancy/lactation o Current 
chemotherapy treatments o Habitual nappi[INVESTIGATOR_007] o Sleep promoting 
medication use (prescribed or over the counter) o Cardio -metabolic 
disease medication use:  
 insulin  
 oral hypogl ycemic medication  
 anti-hypertensive medications  
 hypertriglyceridemia medication 
 medications for low HDL-c 
• Physical exam : All measurements will be completed by a qualified and 
trained RA.  
o Height o Weight o BMI 
o Waist circumference o Blood pressure  
 average of  3 recordings each taken 1 minute apart, following 10 minutes of inactivity.  
 A 4th recording will occur if any two systolic or diastolic readings are >5 mmHg apart. o Neck circumference  
Surveys. Participants enrolled in the study will be asked to complete several surveys. All surveys will be 
completed using REDCap. At home surveys will be administered through the Assessment Center  
Application Programming Interface in REDCap (Research Electronic Data Capture) . For the PROMIS -fatigue 
morning scale and the PR OMIS -fatigue evening scale, the REDCap system will be programed to send two 
separate timed emails, at each time point, to subjects with instructions to answer the questions based on how they felt when they woke up for morning fatigue severity and how they felt when they went to bed for evening 
fatigue severity . 
• CTSI visit 1 surveys o BRICS NINR Demographic Data elements o 
BRICS NINR Demographics (with race clarifying questions)  
o BRICS Demographics - Diagnosis  
 Study Number: 18-[ZIP_CODE] Page 17 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: [ADDRESS_817129] (A UDIT)  
o General health questions  
o PHQ -[ADDRESS_817130] form  
• Baseline Surveys (weeks 1 or 2)  
 Acceptability survey (pre -intervention)  
 Composite Scale of Morningness  
 Economic Vulnerability Survey  
 Family Assessment Device – General Functioning Scale  
 Sleepi[INVESTIGATOR_616323]  
 36-item Short Form Health Survey (SF -36) version 1  
 ASA24  
• The ASA24 (ASA24 -2016) is a freely available web -based tool designed 
to collect self -report dietary recall data. While under - reporting and 
inaccuracy in self -report of dietary intake is a known limitation, 24- hour 
recalls provide more accurate data than other screeners or food 
frequency questionnaires, and the ASA24 has demonstrated similar criterion validity against actual food intaketo other more comp lex and 
time consuming recall methods.  
 Demographics – SDOH: Alcohol use (AUDIT C)  
 Demographics – SDOH: Tobacco use  
 Index of Self -Regulation  
 SAFTEE questionnaire 
 PROMIS- Depression 6a  
• End of study surveys at home (week 15) o 36-item Short Form Health 
Survey (SF-36) version 1  
o ASA24  
 The ASA24 (ASA24 -2016) is a freely available web -based tool designed to collect 
self-report dietary recall data. While under -reporting and inaccuracy in self -report of 
dietary intake is a known limitation, 24- hour recalls provide more accurate data than 
other screeners or food frequency questionnaires, and the ASA24 has demonstrated similar criterion validity against actual food intaketo other more complex and time 
consuming recall methods.  
o Demographics – SDOH: Alcohol use (AUDIT C)  
o Demographics – SDOH: Tobacco use  
o Index of Self -Regulation  
o  o SAFTEE questionnaire 
o PROMIS- Depression 6a  
• Intervention surveys at home (weeks 1- 15) o Epworth Sleepi[INVESTIGATOR_7110] 
(weekly) o PROMIS Fatigue 6a - morning (weekly) o PROMIS Fatigue 6a 
- evening (weekly) o Sleep Diary (daily)  
Objective Sleep and Physical Activity Measures. Participants will wear a wrist accelerometer 24/[ADDRESS_817131] 2- week baseline data collection.  
Training and Treatment Fidelity : SASI facilitators will be individuals with prior training and experience 
delivering sleep interventions. Facilitators will complete training in intervention content and telephone 
 Study Number: 18-[ZIP_CODE] Page 18 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  facilitation skills through didactic instruction and roleplaying. They will be trained to refer  participants to their 
providers for any medical questions.  
All sessions will be digitally audio -recorded using a WebEx conference call line recording capability. A subset 
of 20% of SASI sessions will be reviewed to evaluate treatment fidelity and provide feedback to intervention 
facilitators. Facilitators’ degree of adherence to the protocol will be rated using a SASI Adherence Scale.  
6.1.[ADDRESS_817132] of Care Study Procedures  
Not applicable.  
6.2 Laboratory Procedures/Evaluations  
6.2.1  Clinical Laboratory Evaluations  
Biochemistry: Participants without evidence of fasting glucose, triglyceride, and HDL -c results during the 
previous [ADDRESS_817133] recent blood work. Long term changes in blood lipid levels has been documented as small (0.7% per year) (Glaszious et al 2008). This approach is consistent with other studies examining the relationship betw een 
sleep and metabolic outcomes whereby [CONTACT_616366]’s medical records were used (Reutrakul et. Al 2015).  
The blood specimens will be collected at the NYU Langone Health CTSI Clinical Research Center (CRC) at 
Bellevue Hospi[INVESTIGATOR_307] C/D Building, 4
th floor by [CONTACT_616367]. The estimated total volume of 
blood drawn is 3 ml (for participants needing a fasting glucose, triglyceride, and HDL- c analyses). All 
vacutainer tubes will be labeled with participants’ unique study ID without PHI (e.g. P20+123). The unique 
study ID will stored in a locked cabinet in the PI’s locked office.  
Analysis will be completed at the CTSI lab using standard techniques for analyzing the blood samples. The 
laboratory will report the results through the CRC EMR integration with the NYU Clinical Research 
Management System and REDCap.  
Table 1: Biomarker collection for MetS verification     
Biomarker  Volume 
required  Specimen type  Collection tube  Lab analysis method  Collection 
requirement  
FBG [ADDRESS_817134] 
abstinence requirements. Additionally, to control for diurnal variability we will document the time the patient awoke and evaluate the time lapse during anal ysis. 
6.2.2  Other Assays or Procedures  
Future use of Stored Specimens  
De-identified optional blood samples will be stored for future analysis of biomarkers of metabolic disorders or other health 
conditions, no genetic material will be collected. These optional blood samples will be collected, used, stored, distributed, and 
transferred only in accordance with all applicable laws and regulations, all applicable policies of NYU Langone Health, NYU Langone Health’s IRB Policies and Procedures and the writte n consent and authorization signed by [CONTACT_2330]. The 
 Study Number: 18-[ZIP_CODE] Page 19 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  protocol submitted, reviewed and approved by [INVESTIGATOR_438586]’s IRB will guide the collection of all biomarkers. Written 
informed consent signed by [CONTACT_616368].  
Subjects can opt -out of the optional blood draw and the storage of these specimens in the biorepository through a question on 
the written consent form.  
Subjects will not be contact[CONTACT_616369], as they will provide their consent to store 
and use their samples until they are used up at the time of informed consent. If a subject revokes his/her consent to allow 
storage of his/her samples, the samples will not be drawn.  
Purpose of  Future Research  
The specimens will be shared with members of the research team and the P20 center at NYU Meyers. With the authorization of 
the PI [INVESTIGATOR_17446] P20 center director the samples will be made available to researchers whose scope of work would fall under the 
scope described in the consent and this protocol for analysis of metabolic conditions and other health conditions.  
Type of Sample and Amount  
The optional [ADDRESS_817135] us to wit hdraw 
their samples from s torage (phone numbers, email, and U.S. mailing addresses). This file will be the only file that can link 
subject names, addresses, and/or telephone numbers to the study unique codes and is only accessible by [CONTACT_9154].  
The PI [INVESTIGATOR_616333] P20 research team will have access to the specimens.  
7.3 Study Schedule  
7.3.1 Screening  
Telephone Screening (within 4 weeks of CTSI visit 1)  
• Telephone screen administered (Duration: approximately 15 minutes) o If eligible and 
interested, schedule CTSI visit 1 within 4 weeks of the telephone screen  
• Figure 1 for Multi -stage Screening and Enrollment Flowchart  
Figure 1: Multi- stage Screening and Enrollment Flowchart  
 Study Number: 18-[ZIP_CODE] Page 20 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017   
7.3.2 Enrollment/Baseline  
Enrollment Visit (CTSI Visit 1, within 4 weeks of screening interview): Duration of visit: approximately 
120 minutes  
• Review informed consent form and, if desired by [CONTACT_616370], obtain written informed 
consent. Provide copy of signed form to participant.  
• Review intervention audio consent and, if desired by [CONTACT_616370], obtain written audio consent. Provide copy of signed form to participant.  
• See Table 2 for eligibility measurements and surveys during CTSI Visit 1  
Table 2: Eligibility tests and surveys during Enrollment CTSI Visit 1   
 Number of  
measurements/volume/que  
stions  Estimated time  
Anthropometric measurements   
Height  [ADDRESS_817136] u d y N u m b er: 1 8- 0 0 7 0 7 Pa ge 2 1  
Versi o n Date: Se pte m b er [ADDRESS_817137] u d y s p o ns or Be ha vi oral I nter ve nti o n T e mplate Versi o n: 5 M A Y 2 0 1 7  S ur v e y s    
B RI C S NI N R D e m o gr p a hi c D at a El e m e nt s  n/ a  St u d y t e a m e nt er s  
B RI C S NI N R D e m o gr a p hi c s wit h r a c e cl arif yi n g 
q u e sti o n  1 4  < 5 mi n ut e s  
B RI C S NI N R D e m o gr a p hi c s - Di a g n o si s  n/ a  St u d y t e a m e nt er s  
A R E S q u e sti o n n air e  1 7  < 5 mi n ut e s  
A U DI T  1 0  5 mi n ut e s  
G e n er al h e alt h q u e sti o n s  1 0  < 5 mi n ut e s  
P H Q -9 9 < 5 mi n ut e s  
Pri m ar y C ar e Pr o vi d er  5 < [ADDRESS_817138] F or m  1 2  < 5 mi n ut e s  
T O T A L TI M E   ~ 7 5 mi n ut e s  
• I n str u ct p arti ci p a nt o n t h e u s e of t h e f oll o wi n g ( 2 0 mi n ut e s t ot al):  
o  wri st a c c el er o m et er o  c o n s e n s u s sl e e p di ar y o  s ur v e y s t o b e c o m pl et e d 
d uri n g t h e 2 -w e e k b a s eli n e h o m e a s s e s s m e nt.  
• Arr a n g e f or a m et h o d ( d ail y t e xt s a n d/ or e m ail s s e nt t hr o u g h a s e c ur e e m ail s er v er) f or 
p arti ci p a nt s t o r e c ei v e r e mi n d er s t o c o m pl et e t h e d ail y sl e e p di ari e s a s n e e d e d.  
• Arr a n g e f or a c o n v e ni e nt d a y of w e e k a n d ti m e f or t h e p arti ci p a nt t o r e c ei v e w e e kl y p h o n e or 
vi d e o c o nf er e n ci n g c all s d uri n g t h e i nt er v e nti o n p eri o d.  
7. 3. 3 I nt er m e di at e Vi sit s  
W e e k 1: B a s eli n e D at a C oll e cti o n  
• S e e T a bl e [ADDRESS_817139] u d y r el at e d pr o c e d ur e s d uri n g w e e k 1  
• S e e T a bl e [ADDRESS_817140] et e d d uri n g w e e k 1 or 2.  
• D ail y t e xt s a n d/ or e m ail s will b e s e nt t hr o u g h a s e c ur e e m ail s er v er t o r e mi n d t o p arti ci p a nt s 
t o c o m pl et e t h e d ail y  sl e e p di ari e s a s n e e d e d  Arr a n g e f or pi c k u p or U P S r et ur n of p ul s e 
o xi m et er a s n e e d e d.  
T a bl e 3: B a s eli n e D at a C oll e cti o n W e e k [ADDRESS_817141] a c c el er o m et er a n d fit bit  W e ar 2 4/ 7  n/ a  n/ a  
P ul s e o xi m et er ( a s n e e d e d p er 
pr ot o c ol)  W e ar f or 1 ni g ht  n/ a  n/ a  
D ail y sl e e p di ar y  7 9 < 5 mi n ut e s/ d a y  
< 3 5 mi n ut e s/ w e e k  
P R O MI S F ati g u e 6 a -m or ni n g  1 6 < 5 mi n ut e s  
P R O MI S F ati g u e 6 a - e v e ni n g  1 6 < 5 mi n ut e s  
E p w ort h Sl e e pi n e s s S c al e  1 8 < 5 mi n ut e s/ w e e k  
T O T A L TI M E   < 5 0 mi n ut e s/ w e e k  
 Study Number: 18-[ZIP_CODE] Page 22 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  Table 4: Baseline Surveys Completed during Baseline Weeks 1 or 2   
 Number of questions  Estimated time  
Acceptability Survey (pre -intervention)  7 < 5 minutes  
Composite Scale of Morningness  13 5 minutes  
Economic Vulnerability Survey  8 5 minutes  
Family Assessment Device – General 
Functioning Scale  12 < 5 minutes  
Sleepi[INVESTIGATOR_616323]  11 5 minutes  
36-item Short Form Health Survey (SF - 
36) version 1  36 40 minutes  
ASA24  varies  24 minutes  
Demographics – SDOH: Alcohol use 
(AUDIT C)  3 < 5 minutes  
Demographics – SDOH: Tobacco use  2 < 5 minutes  
Index of Self -Regulation  9 5 minutes  
SAFTEE  128 10 minutes  
PROMIS Depression 6a  6 < 5 minutes  
TOTAL TIME  ~114 minutes  
[IP_ADDRESS] Week 2: Baseline Data Collection  
• Record adverse events as reported by [CONTACT_145855].  
• See Table 5 for study related procedures.  
• Daily texts and/or emails sent through a secure email server will be sent to remind to 
complete the daily sleep diaries as needed  
• Arrange for the pi[INVESTIGATOR_9696] -up or UPS return of the accelerometry devise.  
• Arrange for convenient date/time to call or WebEx videoconference during week 3.  
Table 5: Baseline Data Collection Week [ADDRESS_817142] accelerometer and fitbit  Wear 24/7  n/a n/a 
Daily sleep diary  7 9 < 5 minutes/day  
< 35 minutes/week  
PROMIS Fatigue 6a morning  1 6 < 5 minutes  
PROMIS Fatigue 6a evening  1 6 < 5 minutes  
Epworth Sleepi[INVESTIGATOR_7110]  1 8 < 5 minutes  
TOTAL TIME   ~50 minutes/week  
[IP_ADDRESS] Week 3  
• The study team will evaluate participants ongoing eligibility for SASI based on the accelerometry data confirming that participants are short sleepers.  
• Contact [CONTACT_616371].  
 Retained participants are those who have objectively confirmed MetS , 
objectively confirmed short sleep based on the 2- week baseline home sleep 
test, and objectively confirmed treatment of OS A, if applicable.  
• For retained participants, review baseline week [ADDRESS_817143] week of the intervention.  
• Administer the study intervention in accordance with the SASI protocol.  
 Briefly, bedtimes will be set 15 minutes earlier each week provided sleep 
efficiency remains >90%. Earlier betimes will extend sleep duration by 
[CONTACT_616343]. Wake times will not be changed because 
 Study Number: 18-[ZIP_CODE] Page 23 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  wake times are often determined by  [CONTACT_616344], such as work 
schedules.  
• Arrange for the weekly phone or WebEX videoconferencing meeting to administer the  
intervention for the following week.  
[IP_ADDRESS] Week 4  
• Participant will initiate new sleep schedule as prescribed by [CONTACT_3476].  
• See Table 6 for study related procedures.  
• Send daily text message or email reminders via a secure email server to participants to 
complete their daily sleep diary as needed.  
• Record participant’s adherence to the intervention program.  
• Record adverse events as reported by [CONTACT_145855].  
• Arrange for the weekly phone or WebEx videoconferencing meeting to administer the 
intervention for the following week.  
Table 6: SASI Data Collection Weeks 4 – 13   
 Number of times to 
complete per week  Number of 
questions  Estimated time  
Fitbit Wear 24/7  n/a n/a 
Daily sleep diary  7 9 < 5 minutes/day  
< 35 minutes/week  
PROMIS Fatigue 6a morning  1 6 < 5 minutes/week  
PROMIS Fatigue 6a evening  1 6 < 5 minutes/week  
Epworth Sleepi[INVESTIGATOR_7110]  1 8 < 5 minutes/week  
TOTAL TIME   < 50 minutes/week  
[IP_ADDRESS] Weeks 5 -13 
• Participant will initiate new sleep schedule each week as prescribed by [CONTACT_15328].  
• See Table 6 for study related procedures.  
• Send daily text message or email reminders via a secure email server to participants to complete their daily sleep diary as needed.  
• Record participant’s adherence to the intervention program.  
• Record adverse events as reported by [CONTACT_145855].  
• Arrange for the weekly phone or WebEx videoconferencing meeting to administer the intervention for the following week  
• 
Week 13: Arrange for the delivery of the accelerometry devise by [CONTACT_616372].  
[IP_ADDRESS] Week 14  
• Participant will initiate new sleep schedule as prescribed by [CONTACT_3476].  
• See Table 7 for study related procedures.  
• Send daily text message or email reminders via a secure email server to participants to complete their daily sleep diary as needed.  
• Arrange for the weekly phone or WebEX videoconferencing meeting to administer the intervention for the following week.  
• Record participant’s adherence to the intervention program.  
• Record adverse events as reported by [CONTACT_145855].  
Table 7: Data Collection Week [ADDRESS_817144] accelerometer and fitbit  Wear 24/7  n/a n/a 
Daily sleep diary  7 9 < 5 minutes/day  
< 35 minutes/week  
 Study Number: 18-[ZIP_CODE] Page 24 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  PROMIS Fatigue 6a morning  1 6 < 5 minutes  
PROMIS Fatigue 6a evening  1 6 < 5 minutes  
Epworth Sleepi[INVESTIGATOR_7110]  1 8 < 5 minutes/week  
TOTAL TIME   < 50 minutes/week  
[IP_ADDRESS] Week 15  
• Participant will initiate new sleep schedule as prescribed by [CONTACT_3476].  
• See Table 8 for study related procedures  
• Send daily text message or email reminders via a secure email server to participants at a 
mutually agreed upon time to remind them to complete their daily sleep diary.  
• Record participant’s adherence to the intervention program.  
• Record adverse events as reported by [CONTACT_145855].  
• Arrange for the ret urn of the accelerometry devise to the study team or UPS  
• Arrange for a date and time for the final CTSI visit 2 (Time Point 2, post -intervention) within 
three weeks of completing the intervention  
Table 8: Data Collection Week [ADDRESS_817145] accelerometer and fitbit  Wear 24/7  n/a n/a 
Daily sleep diary  7 9 < 5 minutes/day  
< 35 minutes/week  
PROMIS Fatigue 6a morning  1 6 < 5 minutes  
PROMIS Fatigue 6a evening  1 6 < 5 minutes  
Epworth Sleepi[INVESTIGATOR_7110]  1 8 < 5 minutes  
36-item Short Form Health  
Survey (SF -36) version 1  1 36 40 minutes  
ASA24  1 varies  24 minutes  
Demographics – SDOH: Alcohol 
use (AUDIT C)  1 3 < 5 minutes  
Demographics – SDOH: Tobacco 
use   1 2 < 5 minutes  
Index of Self-Regulation  1 9 5 minutes  
SAFTEE  1 128 10 minutes  
PROMIS Depression 6a  1 6 < 5 minutes  
TOTAL TIME  ~140 minutes/week  
7.4 Final Study Visit (within 3 weeks of completing SASI): Duration < 60minutes  
• Record any new medications prescribed during the study period to treat hyperglycemia, 
hypertension, hypertriglyceridemia, or low HDL-c. 
• See Table 10 for study related procedures.  
• Record adverse events as reported by [CONTACT_145855].  
• Notify participant that aggregate- level results will be available after dissemination of study 
findings begins.  
• Instruct participant to report any subsequent event(s) that the participant, or the participant’s 
physician, believes might reasonably be related to participation in this study.  
Table 10: Fina l Study Visit (at home)   
 Number of questions  Estimated time  
Acceptability survey (post intervention)  7 < 5 minutes  
 Study Number: 18-[ZIP_CODE] Page 25 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  Open ended interview  varies  30 minutes  
TOTAL TIME  ~ 35 minutes  
7.5 Withdrawal Visit  
If a participant withdraws or is withdrawn from the study, no further study visits or procedures will be 
completed.  
7.6 Unscheduled Visit  
Not applicable.  
7.7 Concomitant Medications, Treatments, and Procedures  
Any medications prescribed by [CONTACT_616373], hypertension, 
hype rtriglyceridemia, or low HDL -c levels during study participation will be recorded on the case report forms 
(CRFs). For this protocol, a prescription medication is defined as a medication that can be prescribed only by a 
properly authorized/licensed clinici an. 
8 Assessment of Safety  
8.1 Specification of Safety Parameters  
The study will involve no more than minimal risk to research participants. The probability and magnitude of 
harm or discomfort anticipated for this research are not greater than what this same population encounters in 
daily life or during the performance of physical or psychological examinations or tests. The only alternative to study participation is non- participation.  
8.1.1 Definition of Adverse Events (AE)  
An adverse event (AE) is any sympto m, sign, illness or experience that develops or worsens in severity 
during the course of the study. Intercurrent illnesses or injuries should be regarded as adverse events. Abnormal results of diagnostic procedures are considered to be adverse events if the abnormality:  
• results in study withdrawal  
• is associated with a serious adverse event  
• is associated with clinical signs or symptoms  
• leads to additional treatment or to further diagnostic tests  
• is considered by [CONTACT_1372]  
8.1.2 Definition of Serious Adverse Events (SAE)  
Serious Adverse Event  
Adverse events are classified as serious or non- serious. A serious adverse event is any AE that is:  
• fatal 
• life-threatening  
• requires or prolongs hospi[INVESTIGATOR_4408]  
• results in persistent or significant disability or incapacity  
• a congenital anomaly or birth defect  
• an important medical event  
Important medical events are those that may not be immediately life threatening, but are clearly of major 
clinical significance. They may jeopar dize the subject, and may require intervention to prevent one of the other 
serious outcomes noted above. For example, drug overdose or abuse, a seizure that did not result in in- patient 
hospi[INVESTIGATOR_059], or intensive treatment of bronchospasm in an emergency department would typi[INVESTIGATOR_15355].  
All adverse events that do not meet any of the criteria for serious should be regarded as non- serious adverse 
events.  
 Study Number: 18-[ZIP_CODE] Page 26 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  8.1.3 Definition of Unanticipated Problems (UP)  
Unanticipated Problems Involving Risk to Subjects or Others  
Any incident, experience, or outcome that meets all of the following criteria:  
• Unexpected in nature, severity, or frequency (i.e. not described in study -related documents such  
as the IRB -approved protocol or consent form, the investigators brochure, etc.)  
• Related or possibly related to participation in the research (i.e. possibly related means there is a 
reasonable possibility that the incident experience, or outcome may have been caused by [CONTACT_219000]) 
• Suggests that the research places subjects or others at greater risk of harm (including physical, 
psychological, economic, or social harm).  
8.2 Classification of an Adverse Event  
8.2.1 Severity of Event  
For AEs not included in the protocol defined grad ing system, the following guidelines will be used to describe 
severity.  
• Mild – Events require minimal or no treatment and do not interfere with the participant’s daily activities.  
• Moderate – Events result in a low level of inconvenience or concern with the  therapeutic measures. 
Moderate events may cause some interference with functioning.  
• Severe – Events interrupt a participant’s usual daily activity and may require systemic drug therapy or 
other treatment. Severe events are usually potentially life- threate ning or incapacitating.  
8.2.2 Relationship to Study Intervention  
The clinician’s assessment of an AE's relationship to study intervention is part of the documentation process, 
but it is not a factor in determining what is or is not reported in the study. If there is any doubt as to whether a clinical observation is an AE, the event should be reported. All AEs must have their relationship to study 
intervention assessed. In a clinical trial, the study intervention must always be suspect. To help assess, the 
following guidelines are used
. 
• Related – The AE is known to occur with the study intervention, there is a reasonable possibility that 
the study intervention caused the AE, or there is a temporal relationship between the study 
intervention and event. Reasonable possibility means that there is evidence to suggest a causal 
relationship between the study intervention and the AE.  
• Not Related – There is not a reasonable possibility that the administration of the study intervention 
caused the event, there is  no temporal relationship between the study intervention and event onset, or 
an alternate etiology has been established.  
8.2.[ADDRESS_817146]. Malone will be responsible for determining whether an AE is expected or unexpected. An AE will be 
considered une xpected if the nature, severity, or frequency of the event is not consistent with the risk 
information previously described for the study intervention. As this study is minimal risk, no adverse events are 
expected.  
9.3 Time Period and Frequency for Event Assessment and Follow -Up  
The occurrence of an AE or SAE may come to the attention of study personnel during study visits and 
interviews of a study participant presenting for medical care, or upon review by a study monitor. All AEs 
including local and system ic reactions not meeting the criteria for SAEs will be captured on the appropriate RF. 
Information to be collected includes event description, time of onset, clinician’s assessment of severity, 
relationship to study intervention (assessed only by [CONTACT_616374] h the training and authority to make a diagnosis), 
 Study Number: 18-[ZIP_CODE] Page 27 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  and time of resolution/stabilization of the event. All AEs occurring while on study must be documented 
appropriately regardless of relationship. All AEs will be followed to adequate resolution.  
Any medical  condition that is present at the time that the participant is screened will be considered as baseline 
and not reported as an AE. However, if the study participant’s condition deteriorates at any time during the study, it will be recorded as an AE. UPs will be recorded in the data collection system throughout the study.  
Changes in the severity of an AE will be documented to allow an assessment of the duration of the event at 
each level of severity to be performed. AEs characterized as intermittent require d ocumentation of onset and 
duration of each epi[INVESTIGATOR_1865].  
The PI [INVESTIGATOR_118632] 7 (for non -serious AEs) or 30 days (for SAEs) after the last day of study participation. At each study visit, 
the investigator will inquire about the occurrence of AE/SAEs since the last visit. Events will be followed for 
outcome information until resolution or stabilization.  
All unresolved adverse events should be followed by [CONTACT_1374], the subject 
is lost to follow -up, or the adverse event is otherwise explained. At the last scheduled visit, the investigator 
should instruct each subject to report any subsequent event(s) that the subject, or the subject’s personal physician, believes might reasonably be related to participation in this study. The investigator should notify the 
study sponsor of any death or adverse event occurring at any time after a subject has discontinued or terminated study participati on that may reasonably be related to this study.  
9.4 Reporting Procedures – Notifying the IRB  
9.4.[ADDRESS_817147]; 
cumulative adverse event data; assessments that were performed to evaluate external factors or relevant information that may have an impact on the safety of study participants or ethics of the research study; 
outcomes of procedural reviews conducted to ensure participant privacy  and confidentiality; and final 
conclusions regarding changes to the anticipated risk -to-benefit ratio of study participants and 
recommendations related to continuing, changing, or terminating the study.  
9.4.2 Serious Adverse Event Reporting  
SAEs are not expected due to participation in this minimal risk study. The procedure for AE reporting will be 
followed for SAEs. In addition, if a serious adverse event occurs, it will be reported in a timely fashion after adjudication: All SAE reports will be made to t he IRB within 5 working days; any participant deaths will be 
reported to the NINR Program Officer within 24 hours of realization, and all other serious adverse events will 
be reported to NINR within 72 hours of realization.  
9.4.3 Unanticipated Problem Repo rting  
Incidents or events that meet the OHRP criteria for UPs require the creation and completion of an UP report 
form. It is the site investigator’s responsibility to report UPs to their IRB and to the DCC/study sponsor. The UP 
report will include the following information:  
• Protocol identifying information: protocol title and number, PI’s name, and the IRB project number;  
• A detailed description of the event, incident, experience, oroutcome;  
• An explanation of the basis for determining that the event, incide nt, experience, or outcome 
represents an UP;  
 Study Number: 18-[ZIP_CODE] Page 28 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  • A description of any changes to the protocol or other corrective actions that have been taken or are 
proposed in response to the UP.  
To satisfy the requirement for prompt reporting, UPs will be reported using the following timeline:  
• UPs that are SAEs will be reported to the IRB and to the study sponsor within the timeframe described in 8.4.2 
• Any other UP will be reported to the IRB and to the study sponsor within the timeframe described in  
8.4.1 for AEs.  
• All UPs should be reported to appropriate institutional officials (as required by [CONTACT_17347]’s written reporting procedures), the supporting agency head (or designee), and OHRP within the Time frame described for AEs or SAEs, as appropriate, after the IRB’s re ceipt of the report of the UP from the 
investigator.  
9.4.4 Reporting of Pregnancy  
Pregnant or breastfeeding participants will not be able participate in the study because pregnancy and lactation 
can disrupt habitual sleep patterns, and hormonal changes during pregnancy increase insulin resistance and 
may confound MetS37. If participants become pregnant during the course of the study, their data will not be 
used in the analyses.  
10.5 Reporting Procedures – Notifying the Study Sponsor  
The study clinician will complete a SAE Form within the following timelines:  
• All deaths and immediately life -threatening events, whether related or unrelated, will be recorded on 
the SAE Form and submitted to the DCC/study sponsor within [ADDRESS_817148] information.  
• Other SAEs regardless of relationship will be submitted to the DCC/study sponsor within 72 hours of 
site awareness.  
All SAEs will be followed until satisfactory resolution or until the site investigator deems the event to be chronic 
or the adherence to be stable. Other supporting documentation of the event may be requested by [CONTACT_15791]/study sponsor and should be provided as soon as possible.  
As a follow -up to the initial report, within the following [ADDRESS_817149] the understanding of the event. Significant new information on ongoing unanticipated adverse effects shall be provided promptly to the study sponsor.  
10.6 Reporting Procedures – Participating Investigators  
As the study intervention and data collection will be conducted only at NYU, procedures for monitoring and 
reporting across sites are not provided.  
10.7 Study Halting Rules  
As this study is minimal risk, it is not anticipated that the study may be halted. However, if there is a 
determination of unexpected, significant, or unacceptable risk to participants, the study may be 
temporarily suspended or prematurely terminated as described in section 6.7.  
10.8 Safety Oversight  
It is the responsibility of the Principal Investigator [INVESTIGATOR_616334]/her site. This safety 
monitoring will include careful assessment and appropriate reporting of adverse events as noted above, as well 
as the construction and implementation of a site data and safety -monitoring plan. Medi cal monitoring will 
include a regular assessment of the number and type of serious adverse events.  
 Study Number: 18-[ZIP_CODE] Page 29 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: [ADDRESS_817150] of retrospective and concurrent evaluation of all research procedures, including participant 
screening for inclusion/exclusion criteria, the informed consent process, and participant study instructions, 
as well as any necessary staff training in the IRB approved study protocol. Participant demographics, recruitment, retention, data collection, and data entry updates will be monitored weekly.  
Quality control assurances of data will be reviewed in monthly meetings and will include information about 
missing, invalid, inconsistent data on selected key variables, and a summary of key characteristics of the study 
participants. A random sample of participants’ research records will be reviewed  to ensure compliance with IRB 
requirements, conformance with informed consent requirements, verification of source documents, and 
investigator compliance by [CONTACT_978] [INVESTIGATOR_78384]. Meetings will also be arranged by [CONTACT_978] [INVESTIGATOR_616335].  
Minimizing re search -associated risk. We do not believe that there are any major risks associated with the 
proposed study, although a subject may be identified with moderate/severe or severe depression. This is not a 
research- associated risks but may be detected during screening or participation in the study. The sleep 
intervention and accelerometry monitoring have minimal risk. Trained research personnel will perform all 
testing and will be monitored by [CONTACT_978]. Throughout the study, the PI [INVESTIGATOR_616336]. We have developed the following 
medical alert and reporting policies:  
1. A
RES questionnaire  
a. Scores greater than or equal to six.  
i. Send letter to participant and the participant’s primary care provider, if available, referring the participant to a nearby [CONTACT_616375].  
2. D
epression  
Depressive symptoms will be assessed using PHQ -9 during the screening interview. Individuals identified 
with moderate/severe or severe depression during the screening interview will not be enrolled in the intervention phase of the study as per study protocol. If moderate/severe or severe depression is 
identified, a medical alert and reporting policy has been  developed along with a Depression Safety and 
Referral Plan (see Depression Safety and Referral Protocol and Arranging Care).  
a. PH
Q -9 score ≥[ADDRESS_817151] in 
participating in the study, no language will be used that will indicate any study opportunity/eligibility or personal 
health information unless research personnel are speaking directly with the party of interest. All data from 
participants screened for the study will be entered into the Research Electronic Data Capture (RE DCap) . The 
collected data will be helpful in examining the patient population and feasibility of enrollment criteria and will include gender, age, race, and reason for exclusion. For retained participants, the research staff will collect 
 Study Number: 18-[ZIP_CODE] Page 30 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  and enter required  data (written informed consent and demographics) onto study data forms in REDCap. 
Individuals will be assigned a unique study ID number.  
This study ID number will be linked to the participant name [INVESTIGATOR_13701]. Only the PI [INVESTIGATOR_616337] a ccess to the linkage between the participant identity and the study identification number. This linking file 
will be password protected and stored on a secure NYU server separate from study data. This linking file will 
be destroyed at closure of the study,  and the study will remain open with the IRB until these identifiers are 
destroyed. The unique study identification number will be used on all data forms, and no personal identifiers 
will be connected to the data. Paper records, such as the informed consent documents, will be kept in a locked file cabinet in a locked office. All data will be reported in aggregate.  
Binders. The research coordinator will prepare and maintain a participant -specific binder for each participant 
containing all non- electronic Case Record Files . A regulatory file will also be maintained to include the IRB - 
approved protocol, original informed consent documents, and other study -related regulatory documents. All 
paper research records and case record files will be maintained in a lock ed file cabinet in a secure facility 
within the College of Nursing. Access to the research records, study database and PHI’s will be restricted to study personnel as approved by [CONTACT_978] [INVESTIGATOR_32397].  
Data entry, processing, monitoring. This study will use REDCap  for data capture and management. Data 
exports will be limited to the PI, the research coordinator, and the statistician for generating reports and conducting statistical data analysis . Weekly meetings will include reports on participant recruitment and 
retention, adverse events, and protocol deviations. Monthly meetings will consist of summaries of monthly 
accrual and cumulative accrual, key characteristics of the study participants, and the completeness and quality of data. Information on missing, invalid, and inconsistent data on selected key variables will be 
reviewed.  
Data Security. All data will be saved in an electronic database on a secure NYU server. All system logins, data 
entries, and data updates are recorded, enabling efficient data tracking. Access to the server is available only 
to authorized users with passwords; overall data security is ensured by a firewall. Additional security is 
provided by [CONTACT_616376] a password for data entry and allowing for password protection at 
the record level within a database. Patient confidentiality will be ensured by [CONTACT_616377] . Each participant will be 
identified in the database only by a project -specific ID number . Identifiable information (e.g., name, birthdate, 
home address, or other personal information) will not be stored on any of the devices used in this study . For 
mobile devices and software such as the tablets or cell phones that will be used to gather survey data, 
guidelines established by [CONTACT_616378], incident 
response program, compliance certifications, privacy practices, physical data security, and subcontractors. 
The packages that are shipped to and from study participants will not have any information on the exterior of 
the box indicating that they are a research participant.  
External factors. The PI [INVESTIGATOR_306206]. S hould it 
become clear that the intervention would be in any way harmful to participants, would increase risk, or would be unethical to continue, the IRB and study sponsor will be notified and the study will be stopped.  
Futility analysis. As this pi[INVESTIGATOR_616338] a future well -
powered R01 application, it will not be possible to determine whether the intervention is futile for this population during the proposed study.  
[ADDRESS_817152] of the trial is in compliance with the currently approved protocol/amendment(s), with GCP, and with applicable regulatory 
requirement(s).  
 Study Number: 18-[ZIP_CODE] Page 31 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  Authorized representatives of the IRB and the NINR may review de- identified information, as well as 
participants’ identifiable information, for the purposes of assuring proper conduct of  the research, addressing 
a specific reported incident, or verifying appropriate use of funds. The Quality Assurance and Quality 
Improvement Division of NYU’s Research and Regulatory Services may audit the study to confirm compliance. Access of any protect ed health information will be done in the offices of the PI [INVESTIGATOR_306208]. 
No identifiable information may be copi[INVESTIGATOR_616339] -site. 
The project manager (or clinical research coordinator) will audit one case per quarter, selected at random, 
to confirm  compliance with IRB requirements, including conformance with informed consent requirements, 
verification of source documents, and investigator compliance.  
12 Statistical Considerations  
12.1 Statistical and Analytical Plans  
A formal SAP will be developed for this study in consultation with the study biostatistician. Only a general 
overview of study statistics is included in this protocol.  
12.2 Statistical Hypotheses  
The sample size is too small to make inferences about relationships evaluated in the pi[INVESTIGATOR_616340]. For the primary aim, acceptability will be evaluated by [CONTACT_616379] (overall acceptability survey scores greater than 21), 
neutral (overall acceptabili ty survey scores equal to 21), and unacceptable (overall acceptability survey 
scores less than 21) on the Acceptability Survey at each of two time points (pre- intervention and post 
intervention). Feasibility will be evaluated by [CONTACT_941] 1) recruitment rate: t he percentage of potential participants 
screened in order to enroll 60 participants with evaluable data, 2) attrition rate: the percentage of enrolled participants completing the 18 -week study. Participants will be considered withdrawn after 4 weeks of not  
responding to phone calls/emails during the intervention, and the 3) protocol adherence rates: the percentage 
of participants completing greater than or equal to 4 daily sleep diary entries per week for 80% or more of the 
intervention period. For the secondary endpoints, paired t -tests will be used to compare the mean pre-
intervention and mean post -intervention estimates for SAFTEE scores, physical activity, sedentary behavior, 
diet quality, smoking, alcohol use, affective well -being, morning fatigue, evening fatigue, and self - regulation 
measurements. For the exploratory endpoints of perceived barriers and facilitators of SASI, bivariate correlations between specific socio- ecological factors and sleep duration change will be identified. The 
qualitative data from the post intervention interviews will be analyzed using content analysis. Content analysis includes a line- by-line review that yields clusters of data that are coded. This coding is linked to interview 
questions. Summarization of coding will be performed across individual interviews, and subsequently cross - 
classified to yield a rich descriptive analysis. Emerging themes within and across interviews will be identified, 
and review of fit with data verified.  
12.3 Analysis Datasets  
The analysis dataset  will include all participant (e.g., intent to treat).  
12.[ADDRESS_817153] pi[INVESTIGATOR_616341] a sleep intervention.  
Using descriptive analyses, the investigators will describe each variable using measures of central tendency 
(means, medians) and variability (standard deviations, interquartile ranges) for continuous variables; counts 
and percentages for categorical variables. Data will be evaluated  for anomalies (e.g., nonrandom missing data, 
erroneous outliers, multicollinearity, possible confounding) that may invalidate planned analyses. Data transformations, imputation, and/or robust and tailored analysis approaches will be used for non- normally 
distributed variables.  
 Study Number: 18-[ZIP_CODE] Page 32 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  12.4.2 Analysis of the Primary Efficacy Endpoint(s)  
For Aim 1: Acceptability will be based on the pre - and post -intervention acceptability survey measurements. 
The acceptability survey is an ordinal scale with higher scores indicating greater acceptability. Results will be 
reported as a categorical outcome indicating the count and percentage of participants rating SASI at the pre- 
intervention assessment as well as the post intervention assessment as acceptable (total scores greater t han 
or equal to 21), neutral (total score equal to 21), and unacceptable (total scores less than 21).  
Feasibility will be based on recruitment, retention, and study protocol adherence. Recruitment will be measured 
as the number and percentage of participants screened and their determination as eligible or ineligible based on inclusion/exclusion criteria. Results will be reported as a recruitment rate indicating the count and 
percentage of participants eligible and ineligible. Attrition rates will be reporte d as the number  
and percentage of participants who withdraw from the study. Attrition rates >20% will suggest lack of feasibility. 
Recruitment and attrition rates will also be examined for differences in specific subgroups. Study protocol 
feasibility will be indicated by [CONTACT_616380] 4 work day sleep diaries per week 
for greater than or equal to 80% of the intervention period.  
12.4.3 Analysis of the Secondary Endpoint(s)  
The main secondary endpoint of interest is sleep durat ion. Paired -samples t -tests will be used to compare 
differences in repeated measures of sleep duration (baseline and intervention). Mean sleep duration will be 
calculated as a weighted mean using the formula [(weekday sleep duration x 5) + weekend sleep duration x 
2)]/7. Weekday nights will be Sunday through Thursday nights; weekend nights will be Friday and Saturday nights. The primary secondary outcome for sleep duration data will be obtained from the two- week baseline 
sleep dairy data and the last two weeks of intervention sleep diary data. Other secondary endpoints that will 
be compared between baseline and intervention using paired sample t -tests include measures for 1) diet 
quality (defined as the percentage of fat, percentage of carbohydrate, and total caloric intake estimated from 
the ASA24 at baseline and intervention), 2) physical symptoms (estimated from SAFTEE Questionnaire), 3) 
cigarette and alcohol use estimated from the Demographics - SDOH: Alcohol use (AUDIT C), Demographics 
– SDOH: Tobacco use , 4) affective well -being (estimated from 36- item Short Form Health Survey (SF -36) 
version 1) self - regulation (estimated from the Index for Self -regulation), 6) physical activity (defined as 
moderate/vigorous [100 -429 millgravity units] and light [10- 99 millgravity units]) estimated from the two- 
week baseline accelerometry data and the last two weeks of the intervention accelerometry data, and 8) 
sedentary behavior (defined as less than 10 millgravity units) estimated from the two- week baseline 
accelerom etry data and the last two weeks of the intervention accelerometry data.  
12.4.4 Safety Analyses 
As this study is minimal risk, it is not anticipated that the study may be halted. However, if there is a 
determination of unexpected, significant, or unaccepta ble risk to participants, the study may be 
temporarily suspended or prematurely terminated.  
12.4.5 Adherence and Retention Analyses  
Adherence and retention are the primary endpoints for this pi[INVESTIGATOR_799].  
12.4.6 Baseline Descriptive Statistics  
Baseline characteristics, including demographic and clinical characteristics of the sample, using descriptive 
statistics will be compared between participants for whom the intervention was acceptable and for whom the intervention was unacceptable at each time point (pr e-intervention and post - intervention). Inferential statistics 
will not be used.  
12.4.7 Planned Interim Analysis.  
The research coordinator will prepare weekly reports on participant demographics, recruitment, attrition, and 
protocol adherence. The statistician will prepare monthly reports about missing, invalid, or inconsistent data 
on selected key variables. The reports will also contain a summary of monthly accrual and cumulative accrual, 
 Study Number: 18-[ZIP_CODE] Page 33 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  a summary of key characteristics of the study participants,  and a summary of the completeness and quality of 
data.  
[IP_ADDRESS] Safety Review  
As this study is minimal risk, it is not anticipated that the study may be halted. However, if there is a 
determination of unexpected, significant, or unacceptable risk to participants, the study may be temporarily 
suspended or prematurely terminated . 
[IP_ADDRESS] Efficacy Review  
This study will not evaluate efficacy.  
12.4.8 Additional Sub -Group Analyses 
Primary or secondary endpoints may be analyzed for descriptive purposes by [CONTACT_654], race/ethnicity, or any other 
participant characteristic as described in detail in the SAP.  
12.4.9 Multiple Comparison/Multiplicity  
Not applicable . 
12.4.10 Tabulation of Individual Response Data  
For these analyses, the investigators will generally not control for multiple comparisons.  
12.4.11 Exploratory Analyses  
Explore the perceived barriers and facilitators of SASI (e.g., socio- ecological factors).  
12.5 Sample Size  
Our final sample size is N=60. To achieve this, it is anticipated that 220 interested potential participants will go 
through the telephone screening procedures. The reason we will need to screen 220 is because OSA is often a 
co-morbid condition with MetS and we anticipate 65% of participants screened will become ineligible after the 
initial CTSI visit33. We also anticipate that 20% will not complete the study protocol.  
12.6 Measures to Minimize Bias  
12.6.1 Enrollment/Randomization/Masking Procedures  
Not applicable.  
12.6.2 Evaluation of Success of Blinding  
Not applicable.  
12.6.3 Breaking the Study Blind/Participant Code  
Not applicable.  
13 Source Documents and Access to Source Data/Documents  
Source data is all information, original records of clinical findings, observations, or other activities in a clinical 
trial necessary for the reconstruction and evaluation of the trial. Source data are contained in source documents. Examples of these original documents, and data records include: hospi[INVESTIGATOR_1097], clinical and office charts, laboratory notes, memoranda, subjects’ diaries or evaluation checklists, pharmacy dispensing 
records, recorded data from automated instruments, copi[INVESTIGATOR_110799], microfiches, photographic negatives, microfilm or magnetic media, x -rays, 
 Study Number: 18-[ZIP_CODE] Page 34 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: [ADDRESS_817154] files, and records kept at the pharmacy, at the laboratories, and at medico- technical departments 
involved in the clinical trial.  
The study case report form (CRF) is the primary data collection instrument for the study. All data requested on 
the CRF must be recorded.  All missing data must be explained. If a space on the CRF is left blank because 
the procedure was not done or the question was not asked, write “N/D”. If the item is not applicable to the 
individual case, write “N/A”. All entries should be printed legibly  in black ink. If any entry error has been made, 
to correct such an error, draw a single straight line through the incorrect entry and enter the correct data above it. All such changes must be initialed and dated. DO NOT ERASE OR WHITE OUT ERRORS. For 
clarification of illegible or uncertain entries, print the clarification above the item, then initial and date it.  
Access to study records will be limited to IRB -approved members of the study team. The investigator will permit 
study -related monitoring, audits,  and inspections by [CONTACT_1201]/EC, the sponsor, government regulatory bodies, 
and University compliance and quality assurance groups of all study related documents (e.g. source 
documents, regulatory documents, data collection instruments, study data etc.). The investigator will ensure the capability for inspections of applicable study -related facilities (e.g. pharmacy, diagnostic laboratory, etc.).  
Participation as an investigator in this study implies acceptance of potential inspection by [CONTACT_616381] y authorities and applicable University compliance and quality assurance offices.  
14 Quality Assurance and Quality Control  
QC procedures will be implemented beginning with the data entry system and data QC checks that will be run 
on the database will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
Following written SOPs, the monitors will verify that the clinical trial is conducted and data are generated, 
documented (recorded), and reported in compliance with the protocol, GCP, and the applicable regulatory 
requirements (e.g., Good Laboratory Practices (GLP), Good Manufacturing Practices (GMP)).  
The investigational site will provide direct access to all trial related sites, source data/documents, and reports 
for the purpose of monitoring and auditing by [CONTACT_456], and inspection by [CONTACT_3482].  
15 Ethics/Protection of Human Subjects  
15.[ADDRESS_817155]  
The protocol, informed consent form(s), recruitment materials, and all participant materials have been 
submitted to the IRB for rev iew and approval. Approval of both the protocol and the consent form must be 
obtained before any participant is enrolled. Any amendment to the protocol will require review and approval by 
[CONTACT_3484]. All changes  to the consent form will be IRB 
approved; a determination will be made regarding whether previously consented participants need to be re-
consented.  
15.3 Informed Consent Process  
15.3.1 Consent/Assent and Other Informational Documents Provided to Participants  
Consent forms describing in detail the study intervention, study procedures, and risks are given to the participant 
and written documentation of informed consent is required prior to starting intervention. The following consent 
 Study Number: 18-[ZIP_CODE] Page 35 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  materials are submitted with this protocol Informed Consent, audio consent for interview during the final study 
visit. 
15.3.2 Consent Procedures and Documentation  
Information will be obtained during screening for the study by [CONTACT_430933]. During 
screening,  study staff will review the purpose, nature, risks, and benefits of the study; and determine eligibility. 
The period of time between recruitment and enrollment will be less than or equal to four weeks. This process 
will give the potential participant time  to consider whether he/she wants to participate in the study. Participants 
will be reminded when the study is introduced, during recruitment and screening that participation is voluntary and that choosing not to participate in no way affects the quality or quantity of medical or nursing care provided to them. If at any point the candidate prefers not to proceed, the enrollment visit will be canceled. The candidate will be offered time after the in- person review of the consent form during the enrollment vis it to think 
about her potential participation and to ask any questions before choosing to sign the study consent. In addition, participants are told that they may choose to withdraw from the study at any time.  
Audio informed consents will be obtained for the fidelity checks and for the 30- minute audio -taped open 
ended interview during the final visit. As indicated above, participants will be reminded that participation is 
voluntary and that choosing not to participate in no way affects the quality or quantity of medical or nursing 
care provided to them. The candidate will be offered time after the in- person review of the consent form to 
think about her potential participation and to ask any questions before choosing to sign the study consent. In 
addition, participants are told that they may choose to withdraw from the study at any time.  
Informed consent is a process that is initiated prior to the individual’s agreeing to participate in the study and 
continues throughout the individual’s study participation. E xtensive discussion of risks and possible benefits 
of participation will be provided to potential participants. Consent forms will be IRB -approved and the 
participant will be asked to read and review the document. The investigator will explain the research  study to 
the participant and answer any questions that may arise. All participants will receive a verbal explanation in 
terms suited to their comprehension of the purposes, procedures, and potential risks of the study and of their 
rights as research parti cipants. The participant will sign the informed consent document prior to any 
procedures being done for the study. The participants may withdraw consent at any time throughout the 
course of the trial. A copy of the signed informed consent document will be given to the participants for their records. A copy of the signed informed consent document will be stored in the participant’s research record. 
The consent process, including the name [CONTACT_21811], will be thoroughly documented 
in the subject’s research record. Any alteration to the standard consent process and the justification for such alteration will likewise be documented.  
15.[ADDRESS_817156] of 1996 (HIPAA). Those regulations require a signed 
subject authorization informing the subject of the following:  
o What protected health information (PHI) will be collected from subjects in this study o 
Who will have access to that information and why o Who will use or disclose that information 
o The rights of a research subject to revoke their authorization for use of their PHI.  
In the event that a subject revokes authorization to collect or use PHI, the investigator, by [CONTACT_5151], retains 
the ability to use all information collected prior to the revocation of subject authorization. For subjects that have revoked authorization to collect or use PHI, attempts should be made to obtain permission to collect at least 
vital status (i.e. that the subject is alive) at the end of their scheduled study period.  
Participant confidentiality is strictly held in trust by [CONTACT_3486], their staff, and the spo nsor(s) 
and their agents. This confidentiality is extended to cover testing of biological samples and genetic tests in addition to the clinical information relating to participants. Therefore, the study protocol, documentation, data, and all other informat ion generated will be held in strict confidence. No information concerning the study or the 
data will be released to any unauthorized third party without prior written approval of the sponsor.  
 Study Number: 18-[ZIP_CODE] Page 36 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: [ADDRESS_817157] 
all documents and records required to be maintained by [CONTACT_093], including but not limited to, medical 
records (office, clinic, or hospi[INVESTIGATOR_307]) and pharmacy records for the participants in this study. The  clinical study site 
will permit access to such records.  
The study participant’s contact [CONTACT_179138]. At the end of the study, all records will continue to be kept in a secure location for as long a period as 
dictated by [CONTACT_46202].  
Study participant research data, which is for purposes of statistical analysis and scientific reporting, will be 
transmitted to and stored in the research offices of the PI [INVESTIGATOR_306216]. This will not 
include the participant’s contact [CONTACT_1290]. Rather, individual participants and their research 
data will be identified by a unique study identification number. The study data entry and study management systems used by [CONTACT_616382]. At the end of the study, all study databases will be de -identified and archived at the NYU 
Meyers College of Nursi ng. 
To further protect the privacy of study participants, a Certificate of Confidentiality will be obtained from the NIH. 
This certificate protects identifiable research information from forced disclosure. It allows the investigator and 
others who have acc ess to research records to refuse to disclose identifying information on research 
participation in any civil, criminal, administrative, legislative, or other proceeding, whether at the federal, state, 
or local level. By [CONTACT_175319], Certificates of Confidentiality help achieve the research objectives and 
promote participation in studies by [CONTACT_4205][INVESTIGATOR_21783].  
[ADDRESS_817158] Keepi[INVESTIGATOR_007]  
16.1 Data Collection and Management Responsibilities  
Data collection is the responsibility of the clinical trial staff at the site under the supervision of the site PI. The 
investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  
All source documents should be completed in a neat, legible manner to ensure accurate interpretation of data. 
Black ink is required to ensure clarity of reproduced copi[INVESTIGATOR_014]. When making  changes or corrections, cross out 
the original entry with a single line, and initial and date the change. DO NOT ERASE,  
OVERWRITE, OR USE CORRECTION FLUID OR TAPE ON THE ORIGINAL.  
Copi[INVESTIGATOR_58625] (eCRF) will be provided for use as source documents and maintained for 
recording data for each participant enrolled in the study. Data reported in the eCRF derived from source 
documents should be consistent with the source documents or the discrepancies should be explained and captured in a progress note and maintained in the participant’s official electronic study record.  
Clinical data (including AEs, concomitant medications, and expected adverse reactions data) and clinical 
laboratory data will be entered into REDCap, a data capture system provided by [CONTACT_616383]. The data system includes password protection and internal quality checks, such as automatic range checks, to identify data that appear inconsistent, incomplete, or inaccurate. Clinical data will be entered directly from the 
source documents.  
16.2 Study Records Retention  
Study documents will be retained for the longer of 3 years after close out or 5 years after final 
reporting/publication. These documents should be retained for a longer period, however, if required by [CONTACT_479725]. No records will be destroyed without the written consent of the sponsor, if applicable. It is the 
responsibility of the sponsor to inform the investigator when these documents no longer need to be retained.  
16.[ADDRESS_817159] u d y N u m b er: 1 8- 0 0 7 0 7 Pa ge 3 7  
Versi o n Date: Se pte m b er [ADDRESS_817160] u d y s p o ns or Be ha vi oral I nter ve nti o n T e mplate Versi o n: [ADDRESS_817161] e nt wit h I C H E 6:  
• 4. 5 C o m pli a n c e wit h Pr ot o c ol, s e cti o n s 4. 5. 1, 4. 5. 2, a n d 4. 5. 3  
• 5. 1 Q u alit y A s s ur a n c e a n d Q u alit y C o ntr ol, s e cti o n 5. 1. 1  5. [ADDRESS_817162] b e r e p ort e d t o t h e l o c al I R B p er t h eir g ui d eli n e s. T h e sit e PI/ st u d y 
st aff i s r e s p o n si bl e f or k n o wi n g a n d a d h eri n g t o t h eir I R B r e q uir e m e n t s. F urt h er d et ail s a b o ut t h e h a n dli n g of 
pr ot o c ol d e vi ati o n s will b e i n cl u d e d i n t h e M O P.  
[ADDRESS_817163] s t o s u b mit fi n al p e er -r e vi e w e d j o ur n al 
m a n u s cri pt s t h at ari s e fr o m NI H f u n d s t o t h e di git al ar c hi v e P u b M e d C e ntr al u p o n a c c e pt a n c e f or p u bli c ati o n.  
T h e I nt er n ati o n al C o m mitt e e of M e di c al J o ur n al E dit or s (I C M J E)  m e m b er j o ur n al s h a v e a d o pt e d a cli ni c al tri al s 
r e gi str ati o n p oli c y a s a c o n diti o n f or p u bli c ati o n. T h e I C M J E d efi n e s a cli ni c al tri al a s a n y r e s e ar c h pr oj e ct t h at 
pr o s p e cti v el y a s si g n s h u m a n s u bj e ct s t o i nt er v e nti o n or c o n c urr e nt c o m p ari s o n or c o ntr ol gr o u p s t o st u d y t h e 
c a u s e- a n d -eff e ct r el ati o n s hi p b et w e e n a m e di c al i nt er v e nti o n a n d a h e alt h o ut c o m e. M e di c al i nt er v e nti o n s 
i n cl u d e dr u g s, s ur gi c al pr o c e d ur e s, d e vi c e s, b e h a vi or al tr e at m e nt s, pr o c e s s -of -c ar e c h a n g e s, a n d t h e li k e. 
H e alt h o ut c o m e s i n cl u d e a n y  bi o m e di c al or h e alt h -r el at e d m e a s ur e s o bt ai n e d i n p ati e nt s or p arti ci p a nt s, 
i n cl u di n g p h ar m a c o ki n eti c m e a s ur e s a n d a d v er s e e v e nt s. T h e I C M J E p oli c y, a n d t h e S e cti o n [ADDRESS_817164] er e d i n a p u bli c tri al s 
r e gi str y s u c h a s Cli ni c al Tri al s. g o v, w hi c h i s s p o n s or e d b y t h e N ati o n al Li br ar y of M e di ci n e. Ot h er bi o m e di c al 
j o ur n al s ar e c o n si d eri n g a d o pti n g si mil ar p oli ci e s. F or i nt er v e nti o n al cli ni c al tri al s p erf or m e d u n d er NI H I C 
gr a nt s a n d c o o p er ati v e a gr e e m e nt s, it i s t h e gr a nt e e’ s r e s p o n si bilit y t o r e gi st er t h e tri al i n a n a c c e pt a bl e 
r e gi str y, s o t h e r e s e ar c h r e s ult s m a y b e c o n si d er e d f or p u bli c ati o n i n I C M J E m e m b er j o ur n al s. T h e I C M J E 
d o e s n ot r e vi e w s p e cifi c st u di e s t o d et er mi n e w h et h er r e gi str ati o n i s n e c e s s ar y; i n st e a d, t h e c o m mitt e e 
r e c o m m e n d s t h at r e s e ar c h er s w h o h a v e q u e sti o n s a b o ut t h e n e e d t o r e gi st er err o n t h e si d e of r e gi str ati o n or 
c o n s ult t h e e dit ori al offi c e of t h e j o ur n al i n w hi c h t h e y wi s h t o p u bli s h.  
F D A A A m a n d at e s t h at a "r e s p o n si bl e p art y" (i. e., t h e s p o n s or or d e si g n at e d pri n ci p al i n v e sti g at or) r e gi st er a n d 
r e p ort r e s ult s of c ert ai n " a p pli c a bl e cli ni c al tri al s". NI H gr a nt e e s, s u c h a s t h e PI, will t a k e s p e cifi c st e p s t o e n s ur e 
c o m pli a n c e wit h NI H i m pl e m e nt ati o n of F D A A A, i n cl u di n g r e gi st eri n g t h e tri al wit h cli ni c altri al s. g o v.  
[ADDRESS_817165] a n 4 7 . T h e f u n cti o n of p a y m e nt i n t h e m ar k et m o d el i s t h at of a n i n c e nti v e 
 Study Number: 18-[ZIP_CODE] Page 38 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: [ADDRESS_817166]. Using this model, participants will receive a  $[ADDRESS_817167] at enrollment, a $[ADDRESS_817168] 
after 6- weeks of the intervention is complete, and a $50 when they complete the study, for a total remuneration 
of $[ADDRESS_817169] with this study (patent owne rship, royalties, or financial gain 
greater than the minimum allowable by [CONTACT_1385], etc.) must have the conflict reviewed by [CONTACT_21804] a Committee- sanctioned conflict management plan that has been 
reviewed  and approved by [CONTACT_28833]. All NYULMC investigators will 
follow the applicable conflict of interest policies.   
 Study Number: 18-[ZIP_CODE] Page 39 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: [ADDRESS_817170] of Metformin and Intensive Lifes tyle 
Intervention on the Metabolic Syndrome: The Diabetes Prevention Program Randomized Trial. Ann 
Intern Med. 2005;142(8):611 -619. 
2. Dunkley A, Bodicoat D, Greaves C, et al. Diabetes Prevention in the Real World: Effectiveness of 
Pragmatic Lifestyle Interve ntions for the Prevention of Type [ADDRESS_817171] of 
Adherence to Guideline Recommendations A Systematic Review and Meta-analysis. Diabetes Care. 
2014;37:922 -933. 
3. Geiss LS, James C, Gregg EW, Albright A, Williamson DF, Cowie CC. Diabetes risk reduction 
behaviors among U.S. adults with prediabetes. Am J Prev Med. 2010;38(4):403- 409. 
4. Aziz Z, Absetz P, Oldroyd J, Pronk NP, Oldenburg B. A systematic review of real -world diabetes 
prevention programs: learnings from the last 15 years. Implement Sci. 2015;10:172.  
5. Grandner MA, Chakravorty S, Perlis ML, Oliver L, Gurubhagavatula I. Habitual sleep duration associated with self -reported and objectively determined cardiometabolic risk factors. Sleep Med. 
2014;15(1):42- 50. 
6. Xi B, He D, Zhang M, Xue J, Zhou D.  Short sleep duration predicts risk of metabolic syndrome: a 
systematic review and meta -analysis. Sleep Med Rev. 2014;18(4):293- 297. 
7. Grundy SM, Brewer HB, Jr., Cleeman JI, et al. Definition of metabolic syndrome: Report of the 
National Heart, Lung, and Blo od Institute/American Heart Association conference on scientific issues 
related to definition. Circulation. 2004;109(3):433- 438. 
8. Centers for Disease Control and Prevention. Short Sleep Duration Among Workers — [LOCATION_002], 
2010. MMWR 2012;61(16):281 -282. 
9. Tasali E, Chapotot F, Wroblewski K, Schoeller D. The effects of extended bedtimes on sleep duration and food desire in overweight young adults: a home- based intervention. Appetite. 
2014;80:[ADDRESS_817172] of sleep extension on fasting insulin 
sensitivity in adults with habitual sleep restriction. Sleep. 2015;38(5):707- 715. 
11. Haack M, Serrador J, Cohen D, Simpson N, Meier -Ewert H, Mullington JM. Increasing sleep duration 
to lower beat -to-beat blood press ure: a pi[INVESTIGATOR_799]. J Sleep Res. 2013;22(3):295- 304. 
12. Nicklas BJ, Beavers DP, Mihalko SL, Miller GD, Loeser RF, Messier SP. Relationship of Objectively -
Measured Habitual Physical Activity to Chronic Inflammation and Fatigue in Middle - Aged and Older 
Adults.  J Gerontol A Biol Sci Med Sci. 2016;71(11):[ADDRESS_817173], Ryff CD, Kubzansky LD. Subjective well -being and 
cardiometabolic health: An 8- 11year study of midlife adults. J Psychosom Res. 2016;85:1- 8. 
14. Welty FK, Alfaddagh A, Elajami TK. Targeting inflammation in metabolic syndrome. Transl 
Res.
2016;167(1):257- 280. 
15. Patel S, Zhu X, Storfer_Isser A, et al. Sleep Duration and Biomarkers of Inflammation. Sleep.
2009;32(2):200-204.  
16. Xiao J, Shen C, Chu MJ, et al.  Physical Activity and Sedentary Behavior Associated with 
Components of Metabolic Syndrome among People in Rural China. PloS one. 2016;11(1):e0147062.  
17. Wijndaele K, Orrow G, Ekelund U, et al. Increasing objectively measured sedentary time increases 
clustered cardiometabolic risk: a 6 year analysis of the ProActive study. Diabetologia. 2014;57:305- 
312. 
18. Amini M, Esmaillzadeh A, Shafaeizadeh S, Behrooz J, Zare M. Relationship between major dietary patterns and metabolic syndrome among individuals with impaired  glucose tolerance. Nutrition. 
2010;26(10):986- 992. 
19. Xiao Q, Keadle SK, Hollenbeck AR, Matthews CE. Sleep duration and total and cause-specific 
mortality in a large US cohort: interrelationships with physical activity, sedentary behavior, and body 
mass inde x. Am J Epi[INVESTIGATOR_5541]. 2014;180(10):997- 1006.  
20. Kant AK, Graubard BI. Association of self -reported sleep duration with eating behaviors of American 
adults: NHANES 2005- 2010. Am J Clin Nutr. 2014;100(3):938- 947. 
21. Haack M, Mullington JM. Sustained sleep restriction reduces emotional and physical well - 
being. Pain. 2005;119(1- 3):56- 64. 
22. Gohar A, Adams A, Gertner E, et al. Working Memory Capacity is Decreased in Sleep -Deprived 
Internal Medicine Residents. Journal of Clinical Sleep Medicine. 2009;5(3):191-197.  
 Study Number: 18-[ZIP_CODE] Page 40 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  23. Shieh C, W eaver MT, Hanna KM, Newsome K, Mogos M. Association of Self -Efficacy and Self - 
Regulation with Nutrition and Exercise Behaviors in a Community Sample of Adults. J Community 
Health Nurs. 2015;32(4):199- 211. 
24. Buxton OM, Pavlova M, Reid EW, Wang W, Simonson DC, Adler GK. Sleep restriction for 1 week 
reduces insulin sensitivity in healthy men. Diabetes. 2010;59(9):2126 -2133.  
25. Robertson MD, Russell -Jones D, Umpleby [CONTACT_162702], Dijk DJ. Effects of three weeks of mild sleep 
restriction implemented in the home environment on multiple metabolic and endocrine markers in 
healthy young men. Metabolism. 2013;62(2):204- 211. 
26. Lauderdale DS, Knutson KL, Yan LL, et al. Objectively measured sleep characteristics among early -
middle -aged adults: the CARDIA study. Am J Epi[INVESTIGATOR_5541]. 2006;164(1) :5-16. 
27. Spaeth AM, Dinges DF, Goel N. Resting metabolic rate varies by [CONTACT_616384]. Obesity 
(Silver Spring). 2015;23(12):2349- 2356.  
28. Grandner MA, Jackson NJ, Izci -Balserak B, et al. Social and Behavioral Determinants of Perceived 
Insufficient S leep. Front Neurol. 2015;6:112.  
29. Williams NJ, Grandner MA, Wallace DM, et al. Social and behavioral predictors of insufficient sleep 
among African Americans and Caucasians. Sleep Med. 2016;18:103 -107. 
30. Fang SC, Subramanian SV, Pi[INVESTIGATOR_2399] R, et al. Geographic variations in sleep duration: a multilevel 
analysis from the [LOCATION_011] Area Community Health (BACH) Survey. J Epi[INVESTIGATOR_47779]. 
2015;69(1):63- 69. 
31. Irwin MR, Cole JC, Nicassio PM. Comparative meta- analysis of behavioral interventions for insomnia 
and th eir efficacy in middle -aged adults and in older adults 55+ years of age. Health psychology : 
official journal of the Division of Health Psychology, American Psychological Association. 
2006;25(1):3- 14. 
32. Wu JQ, Appleman ER, Salazar RD, Ong JC. Cognitive Behavioral Therapy for Insomnia Comorbid With Psychiatric and Medical Conditions: A Meta-analysis. JAMA Intern Med. 2015;175(9):[ADDRESS_817174] of obstructive sleep apnea on metabolic and 
inflammatory markers in consecutive patients with metabolic syndrome. PloS one. 2010;5(8):e12065.  
34. Luckhaupt S, Tak S, Calvert G. The Prevalence of Short Sleep Duration by [CONTACT_616385]. Sleep. 2010;33(2):149- 159. 
35. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim 
statement of the International Diabetes Federation Task Forc e on Epi[INVESTIGATOR_21893]; 
National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. 
Circulation. 2009;120(16):1640-1 645. 
36. Morgenstern M, Wang J, Beatty N, Batemarco T, Sica AL, Greenberg H. Obstructive sleep apnea: an 
unexpected cause of insulin resistance and diabetes. Endocrinol Metab Clin North Am. 
2014;43(1):187- 204. 
37. Buchanan T, Metzger B, Freinkel N, Bergman R. Insulin sensitivity and B -cell responsiveness to 
glucose during late pregnancy in lean and moderately obese women with normal glucose tolerance 
or mild gestational diabetes. American Journal of Obstetrics and Gynecology. 1990;162(4):1008 - 
1014.  
38. Rha SY, Lee J. Symptom clusters during palliative chemotherapy and their influence on functioning 
and quality of life. Supportive care in cancer : official journal of the Multinational Association of 
Supportive Care in Cancer. 2017;25(5):1519 -1527.  
39. Brooks AT, Krumlauf M, Fryer CS, et al. Critical Transitions: A Mixed Methods Examination of Sleep 
from Inpatient Alcohol Rehabilitation Treatment to the Community. PloS one. 2016;11(8):e0161725.  
40. Tsuno N, Besset A, Ritchie K. Sleep and Depression. Journal of Clinical 
Psychiatry.
2005;66(10):1254- 1269.  
41. Monk TH, Buysse DJ, Kennedy KS, Potts JM, DeGrazia JM, Miewald JM. Measuring Sleep Habits 
Without Using a Diary: The Sleep Timing Questionnaire. Sleep. 2003;2:208- 212. 
42. Bastien C, VallieÁres A, Morin CM. Validation of the Insomnia Severity Index as an outcome measure for insomnia research. Sleep Medicine. 2001;2:297- 307. 
43. Bohn M, Babor T, Kranzler H. The Alcohol Use Disorders Identification Test (AUDIT): Validation of a Screening Instrument for Use in Medical Settings. J Stud Alcohol. 1995;56:423 -432. 
 Study Number: 18-[ZIP_CODE] Page 41 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the property of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as 
authorized in writing by [CONTACT_248690]: 5 MAY 2017  44. Bellg AJ, Borrelli B, Resnick B, et al. Enhancing treatment fidelity in health behavior change studies: 
best practices and recommendations from the NIH Behavior Change Consortium. Health psychology 
: official journal of the Division of Health Psychology, American Psychological Association. 
2004;23(5):443- 451. 
45. Callaway C, Chumlea, W., Bouchard, C., Himes, J., Lohman, T., Martin, A., Mitchell, C., Mueller, W., 
[COMPANY_002], A., Seefeldt, V. Circumferences. In: Lohman T, [COMPANY_002], A., Mar torell, R., ed. Anthropometric 
Standardization Reference Manual . Chanmpaign, Illinois: Human Kinetics Books; 1988:39- 54. 
46. Dickert N, Emanuel E, Grady C. Paying research subjects: An analysis of current policies. Annals of 
Internal Medicine. 2002;136(5):368 -373. 
47. Punjabi, N. et al. Sleep disordered breathing and cardiovascular disease: An outcome- based 
definition of hypopneas.  
Am J Respir Crit Care Med 2008: 117, 1150 -1155.  
48. Punjabi, N., Aurora, R., Patil, S. Home sleep testing for obstructive sleep apnea: One night is enough! Chest. 2013:143, 291 -294 
Study Number: 18-[ZIP_CODE] Page 42 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the prop erty of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as authorized in writing by [CONTACT_616386]: 5 MAY 2017  Attachment A  
Schedule of Events  
Activity  Recruitment ≤ 
4 weeks  
Enrollment 
CTSI Visit 1  Baseline 
Week 1  Baseline 
Week 2  Intervention 
Weeks 3 -13 Intervention 
Week 14  Intervention 
Week 15  Final Visit  
≤ [ADDRESS_817175] Measurements   X       
Blood Pressure   X       
Blood Samples   X as needed        
Text/email daily 
diary reminders 
as needed   
X X X X X X  
Weekly Intervention 
Call     X X X  
Assess for AEs,  
SAEs, UPs      X X X  
Fitbit wear time    X X X X X  
Deliver accelerometer   X   X during week 
13    
Accelerometer wear 
time   X X  X X  
Pi[INVESTIGATOR_7049]/drop off 
accelerometer     X 
after week 2    X 
after week 15   
Study Number: 18-[ZIP_CODE] Page 43 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the prop erty of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as authorized in writing by [CONTACT_616386]: [ADDRESS_817176]-intervention 
Interview         X 
Surveys          
CTSI 
screening and 
enrollment 
surveys          
Data Elements   
X       
Additional Element  
Group – Form  
Administration   X       
BRICS NINR  
Demographics with race 
clarifying questions   X       
BRICS NINR  
Demographics - 
Diagnosis   X       
ARES   X       
AUDIT   X       
General Health  
Questions   X       
PHQ -[ADDRESS_817177]-intervention  
Composite Scale of 
Morningness    X      
Study Number: 18-[ZIP_CODE] Page 44 
Version Date: September 27, 2019  
CONFIDENTIAL  
This material is the prop erty of the NYU School of Medicine and Langone Medical Center. Do not disclose or use except as authorized in writing by [CONTACT_616386]: 5 MAY 2017  Economic Vulnerability 
Survey    X      
Family Assessment  
Device- General  
Functioning Scale    X      
Sleep Environment 
Survey    X      
Baseline and End of  
Study Surveys          
 
36-item Short Form  
Survey (SF -36) version  
1   X      
ASA24    X    X  
Demographic - SDOH:  
Alcohol use (AUDIT C)    X    X  
Demographic - SDOH: 
Tobacco use    X    
X  
Index of Self - regulation    X    X  
SAFTEE    X    X  
PROMIS Depression 6a    X    X  
Weeks 1 -15 Surveys          
PROMIS Fatigue  
6a morning    X X X X X  
PROMIS Fatigue  
6a evening    X X X X X  
Epworth Sleepi[INVESTIGATOR_7109]    X X X X X  
Daily Sleep Diary    X (daily)  X (daily)  X (daily)  X (daily)  X (daily)   
 